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1. INTRODUCTION 
Alopecia areata is a common skin condition characterized by localized hair loss 
usually over the scalp region. But the condition is frequently seen in children. Both sex 
are equally affected although some study report a male -to-female ratio 2:1 
1.
Prevalence 
is approximately 0.2% of the population and lifetime risk is believed to be between 1% 
and 2%.There is a history of familial occurrence in 10% - 20% of the affected 
individuals
2 
Incidence of the disease is 17.2/100,000 population affecting 1:1000 
individuals at a given time 
3
.  Hair loss not only in scalp region but also in hair bearing 
areas. 
 
A complete hair loss of the scalp is seen in alopecia totalis.  Alopecia of all hair- 
bearing surfaces   including eye lashes, eye brows, body hair seen in alopecia universalis. 
In ophiasis a circumferential hair loss extending around the temporal and occipital 
hairlines. Scarring alopecia or cicatricial alopecia represents a group of disorders 
characterized by permanent and pathological destruction of the hair follicles. Scalp is the 
commonest site but lesion may present at other sites even without involvement of the 
scalp. 
 
Alopecia areata is not a contagious disease. It is not associated with any scalp 
finding such as scale or inflammation.  Exclamation mark hair indicates active disease. 
Dystrophic nail changes occur in 20% case. Recurrence of alopecia are frequently occur 
in over 50% . Spontaneous recovery is very common in children before puberty 
1
. It 
affects all age group and the first episode usually occur in patient less than 25 years of 
age 
3 
. Lifetime risk of alopecia areata is increased in individuals with personal or family 
history of autoimmune disorders such as vitiligo, thyroid disease and pernicious anemia. 
 
Alopecia areata is an autoimmune disease of the hair follicle. Alopecia areata 
typically presents with sudden appearance of one or more round or oval well defined 
patches of hair loss. The common cause of non-scarring hair loss in children. The hair 
loss may occur overnight or over a period of several days. In some children, the initial 
patch may not be well defined and may show scattered long hairs within the bald area. 
Occasionally, the initial loss may be diffuse and the patches of baldness may be 
apparently only after 1 or 2 weeks.  
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Alopecia areata associated with atopy; nail changes as pits, ridges, opacification, 
and serration of the free nail edge, dystrophy and red lunula. 
 
An increased incidence of alopecia areata has been reported in patients with 
down‟s syndrome (5-10%)4. The cause of alopecia areata is unknown. Emotion factor 
and stress have been suggested as triggering factor.There is no cure for Alopecia and no 
universally proven therapy to induce hair growth. 
 
The basic principle of Siddha system of Medicine is Panchapootham theory. 
According to Panchapootham theory the universe is made up of five elements of 
nature.The human body is also made up of five elements. Alerations of the three vital 
humours Vali, Azhal and Iyyam which leads to disease manifestation. 
 
In siddha alopecia is denoted as puzhuvettu in the text book Sirappu  
Maruthuvam
5
. According to Mukkuttram concept Puzhuvettu is consider as vadha 
disease “Vathamaladhu meni kedadhu”6. In Siddha system of medicine, there are 4448 
group of disease are classified in   humanbeing. Among 4448 group of disease kurumi 
noi is described in the text of Noi Nadal Thirattu
6
. Kirumi is one of the reason of 
Puzhuvettu. 
 
Prevention and treatment are the basic aim of the siddha system of medicine. 
Siddha system is a vast and unique system which defines health as a prefect state of 
physical, psychological, social and spiritual well being of an individual. In siddha 
medicine there is not only cure of disease but also improve the quality of life by 
prevention and rejunuvating. In NIS OPD a considerable number of patients in pediatric 
population are recorded with the symptoms of puzhuvettu. 
 
Puzhuvettu is not a contagious disease but it may have to complex comparing in 
the schools and their surrounding environment. Preschool age Children who have 
alopecia don‟t experience as much emotional impact from their condition. Between the 
age of six and twelve they are noticing differences between themselves and others. They 
may be mentally affected and feel shy which reflects in their academic, attitude and 
performance skill. Cosmetically it remains a great problem in children and causing stress 
in parents. 
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A Siddha drug Silvisha Usidham (Internal) and Puzhuvettu thylam (External) 
both are indicated for the treatment of Puzhuvettu in the text book of Siddha Anuboga 
Vaithiya Navaneedha Thirattu
7
. All the ingredients of trail drug are a composition of 
herbal only. Silvisha Usidham which constitutes Elleteria cardamomum, Ficus hispida, 
Sesame oil and Piper longum having Anti- inflammatory activity, immunomodulator, 
anti microbial and anti-fungal activites. Puzhuvettu thylam which constitutes Ricinus 
communis (castor oil), Shorea robusta and Indigofera tinctoria having hair growth 
promoting  activity.  So it is safe and have efficacy in treating puzhuvettu in children. 
 
Since the formulation does not undergone any clinical trial so far. In  order to 
manage the disease with a simple herbal  formulation has been selected as dissertation 
work. The medicine is proved to have a good impact on this condition it will serve as a 
great benefit to the paediatric population who suffer from alopecia areata. 
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2. AIM AND OBJECTIVES 
 
AIM: 
                 To evaluate safety and efficacy of Silvisha Usidham (Internal Medicine) and 
Puzhuvettu Thylam (External Medicine) for Puzhuvettu (Alopecia areata) in children. 
 
OBJECTIVES: 
 
1. To collect and review the ideas mentioned in the ancient Siddha literature about the 
disease Puzhuvettu. 
2. To make correlative study of the Siddha and modern aspect of this disease. 
3. To study the characteristics  of Puzhuvettu with that of alopecia areata in children on 
the basis of uyir thathukkal, udal thathukkal, envagaithervugal, Paruvakaalangal, 
age, sex and economic status. 
4. To study the Physiocochemical properties, Biochemical analysis and Phytochemical 
analysis. 
5. To Study the Pharmacological activity of the Silvisha Usidham. 
6. To evaluate the toxicity profile of Silvisha Usidham.   
 
 
 
 
 
 
 
 
 
 
 
 
- 
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3. REVIEW OF LITERATURE 
3.1. SIDDHA ASPECT 
                                                         Alopecia areata 
 
  புழுவயட்டு - தல஬னில் திட்டுத்திட்டாக ப௃டி உதிர்ந்து அவ்யிடங்கள் 
யழுக்லகனாகக்காணப்஧டும். 
 
வயறு வ஧னர்கள் : 
                நனிர்உதிபல், தல஬ நனிர்வயட்டு, புழுக்கடி 
 
AETIOLOGY (NOI VARUM VAZHI):  
 
ACCORDINGN TO “GURUNAADI NOOL” 
      
வ஥ாய் காபணம் : 
                “கிபேநினால் யந்த வதாடம் வ஧பேகவுண்டு 
                 வகட்கயதின் ஧ிரியதல஦க் கிபநநாக 
                 வ஧ாபேநி யபேம்யாப௅ வயல்஬ாங் கிபேநினாவ஬ 
                 புழுக்கடி வ஧ால் காணுநது கிபேநினாவ஬ 
                 வெபேநி யபேம் ஧வுத்திபங்கள் கிபேநினாவ஬ 
                 வதகநதில் வொலகக் குட்டம் கிபேநினாவ஬ 
                 துபேநி யபேஞ் சுவபாணிதங் கிபேநினாவ஬ 
                 சூட்ெப௃டன் கிரிலெப்஧ால் வதாமில் வெய்யவீப “ 
       -குபே஥ாடி நூல் 
 
The cause of Puzhuvettu is explained in Gurunaadi Nool.“Puzhukadi pol 
kaanumadhu  kirumiyalae”  Infection is one of the reason that causing puzhuvettu. 
 
6 
 
ACCORDING TO THEYRAIYAR: 
      “யாதந஬ாது வந஦ி வகடாது” 
      As per the Siddha literature the body get affected mainly due to vitiation of vatha 
humour including skin condition. 
 
The characteristic features of puzhuvettu described in the text Siddha Maruthuvam 
Sirappu. They are 
 
1. Patchy hair loss in scalp region. 
2. It is one of infectious disease.  
3. Initially hair loss starts with small area after that it increase in size and baldness 
occur. 
 
          தல஬னில் திட்டுத்திட்டாக ப௃டி உதிரிந்து அவ்யிடங்கள் யழுக்லகனாகக் 
காணப்஧டும், எபேயலகக் கிபேநிவ஥ாலனப் புழுவயட்டு ஋ன்கிவ஫ாம், நனிர் 
உதிர்ந்த  இடங்கள்  நினுநினுப்஧ாய்த்  வதான்றும், எபே ெி஫ின இடத்தில் 
ஆபம்஧ித்து நனிர் உதிபல், கூடிக்வகாண்வடவ஧ாய் யழுக்லகத்திட்டு 
வ஧ரிதாகிக்வகாண்டு  யபேம்5. 
                                                                                                      
Varieties of puzhuvettu : 
 
1. Loss of hair in scalp region. 
The main symptom of hair loss in patches and scarring is described in the text 
“Siddhar Aruvai Maruthuvam” 8 under kabala kirumi that too purakirumi –They 
cannot be treated. 
 
2. Hair loss in eyebrows and eyelashes. This type of Puzhuvettu explained in the 
text of  “Nagamuni Nayanavithi” 
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பு஫க்கிபேநி – (நண்லடகிபேநி) 
1. “ தாவ஦ க஧ா஬ப் பு஫க்கிபேநி தக்க குணத்லதச் ொற்஫க்வகள் 
               நாவ஦ தல஬னி லுவபாநவந஬ாம் யடுயா ப௅திர்ந்து தழும்஧ாகும் 
               வ஧வ஦பெபேம் வ஧ாலூபேம் ஧ின்னுஞ்ொம்஧ல் வ஧ாபேக்கு யிழும் 
              வதவ஦ னிந்தக் குணந஫ிந்தாற் வெய்ப௅ நபேந்லதத் வதர்ந்த஫ிவன “ 
                                                                                                - அறுலய  நபேத்துயம் 
 
      2.  “வ஧ாதவய னிலநக ஦த்துப் வ஧ாங்கின தி஦வுண்டாகும் 
ப௄தவய வனரிப்புண்டாகு ப௃திர்ந்திடும் நனிர்க்கா,வ஬ல்஬ாங் 
காதவய தல஬கால் வநய்கள் கபகப வயன்று வதான்றுங் 
வகாதவய னிலநகள் தானுங் வகாடும்புழுவயட்ட தாவந “   
                                                                                         -அகத்தினர் ஥ன஦யிதி 
 
வகாடும் புழுவயட்டின் ஧ண்பு – இலநனில் ஌ற்஧டும் நனிர்வயட்டு 
 
The main symptoms of Puzhuvettu are explained very well in the above verse 
(Agasthiyar  Nayanavithi). They are 
 
1. Itching 
2. Tingling sensation 
3. Hair loss 
4. Inflammatory changes in hair follicles 
 
“உள்஭ிலந  யி஭ம்஧ி லூறு ப௃வபாம்ப௃ ப௃திபேம் புண்ணாய் 
வதள்஭மல் வ஧ா஬க் காந்தும் ஏடுவந னிபத்தந் தானும் 
வயள்஭ிலட ெியக்க யஙீ்கித் தடித்திடு நிக்கு ணங்கள் 
அள்஭ில஬ வ஥டுவயற் கண்ணாய் புழுக்கடிக் குணவந தாவந” 
- ஥ாகப௃஦ி ஥ன஦யிதி 
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நனிர்ப்புழுவயட்டு 
“஥ீட்டின தி஦வுங் கூச்ெம் ஥ீர்யபே நிலநப௅ம் யகீ்கம் 
கூட்டிடும் ஧ீல஭ வெபேம் குறுப௃ல஭ப் வ஧ா஬த் வதாற்஫ம் 
஥ாட்டிவன நனிபேதிர்ந்து ஥ற்ெலத பத்தம் யழீும் 
காட்டிது நனிர்ப்புழு வயட்டு கண்டய பேலபத்த யாவ஫ “ 
- அகத்தினர் ஥ன஦யிதி 
 
DIAGNOSTIC METHODS (PINIYARI MURAIMAI): 
         Piniyari Muraimai is the methods of determination of a disease. It is based on the 
following principles. 
1. Poriyalarithal 
2. Pulanal arithal 
3. Vinaathal 
 
Poriyalarithal and Pulanalarithal goes hand to hand with the concept of 
examining the patient‟s Pori and Pulan with that of  physician‟s  Pori and Pulan. 
 
Vinaathal is a method of enquring about the details of that patients problem from 
his own words or from his parents or neibhours who are taking care of the patients, when 
the patient is not able to speak or patient may be child. 
 
ENNVAGAI THERVUGAL (EIGHT DIAGNOSTIC TOOLS): 
 
  “஥ாடி ஸ்஧ரிெம் ஥ா஥ி஫ம் வநாமி யிமி 
 ந஬ம் ப௄த்திபநிலய நபேத்துய பாப௅தம்” 
- வதபன் வயண்஧ா 
 
“வநய்கு஫ி ஥ி஫ம் வதா஦ி யிமி ஥ா இபேந஬ம் லகக்கு஫ி” 
It is also given in Agasthiyar Vaithiya Chinthamani Venba -4000  
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Hence the diagnosis is made by the following: 
1. Naadi (Pulse reading) 
2. Sparisam (Tactile sensation) 
3. Naa (Tongue) 
4. Niram (Colour) 
5. Mozhi (Speech or voice) 
6. Vizhi (Eyes) 
7. Malam (Stools) 
8. Moothiram (Urine) 
  
ENVAGAI THERVUGAL: 
1. NAADI : 
஋ண்யலகத் வதர்வுக஭ில் ஧ிபதா஦நா஦து. ஧ிணினில஦ ஥ாடினா஬஫ிந்து 
நபேந்தூட்டுதவ஬ ெி஫ந்தது ஋ன்று ெித்த நபேத்துயம் கூறுகின்஫து. ஆ஦ால் 
குமந்லதக஭ில் ஥ாடி஥லட ெரினாக வதான்஫ாது ஋ன்஧லத கீழ்கண்ட ஧ாட஬ால் 
அ஫ின஬ாம். 
 
    “வகாண்டிடவய  கனவபாகி  காெவபாகி 
     கு஫ிப்஧ாக ெிற்஫ின்஧ம் வெய்த வ஧ர்கள் 
     அண்டிடவய தரித்திபர்கள் யிபேத்தர் ஧ா஬ர் 
      வகாண்டிடவய  இயர்க஭ின்  உறுப்஧ின் தாது 
      கூ஫வய ப௃டினாது  ஋யர்க்குக்  கிட்டும்” 
                            -வ஥ாய்஥ாடல் வ஥ாய் ப௃தல்஥ாடல் திபட்டு  
 
யாதம் நிகுதினால் யபேம்  வ஥ாய்கள்: 
    “யாதவநனும் ஥ாடினது வதான்஫ில் 
      ெதீநந்தவநாடு யனிறு வ஧ாபேநல் திபட்ெி யாய்வு 
     ெதீப௃றுங் கிபாணி நவகாதபம் ஥ீபாலந 
      திபள்யாய்வு சூல஬ ய஬ிகடுப்புத் தலீப 
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     ஥ீதப௃றுங் கிபேநிகுன்நம் அண்ட யாதம் 
      ஥ில஬ப௅ம்஥ீர்க் கிரிச்ெபங்கள் தந்து வநகம் 
     வ஧தகநா ப௃தபப்஧ிணி ப௄஬ வபாகம் 
      வ஧ெவயகு ஧ிணிகல௃வந வ஧ாபே஭ தாவந” 
                              - அகத்தின஦ார் ெிகிச்ொபத்஦த஧ீம் 
இதல஦ யாதத்தில் யாதம்,யாத கதித்தல்,யாதம்நீ஫ி ஥டத்தல் ஋஦வும் 
கூறுயர்.  
 
2. SPARISAM : 
The following points are elicited by sparisam temperature of the skin on any 
abnormal grounds, hypersensitiveness and thickness of the skin, swelling and 
dryness of the skin, excessive sweating, hair loss, ulcers, oedema, obesity, liver and 
spleen enlargement. 
In puzhuvettu  patchy hair loss in scalp region. 
    
3. NAA : 
This is the method of inspection of the tongue, gums, Teeth, lips, palate etc No 
Abnormalities were observed in Puzhuvettu. 
 
4. NIRAM: 
Changes in the color of the skin, teeth, eyes, nail and lips due to Mukkutra 
derangement are to be noticed. In Scarring alopecia there is colour change in affected 
area. 
        
5. MOZHI :              
Examination of mozhi includes clarity of speech, crying, low & high piched 
voice and slurring speech. No abnormalities were observed in puzhuvettu. 
 
6. VIZHI: 
Pallor of the conjunctiva, conjunctivitis, Cataract (any redness) In Puzhuvettu 
hair loss in eyebrows and eye lashes. 
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7.  MALAM :  
            Semisolid, color froth, abnormal consistency indicating indigestion, 
frequency,  constipation,  foul smell etc. 
 
8.  MOOTHIRAM : 
Collection of urine for the determination of Neerkuri and Neikuri. It is an 
important diagnostic method. 
 
Neerkkuri: 
The previous day of urine examination the patient should have good sleep and 
instructed to take a balanced diet. After waking up in the morning, the first voiding of 
urine is collected in a clear wide mouthed glass container and is subjected to analysis of  
“Neerkuri”  within 1 1/2hours. 
 
Urine has the following general features: 
Niram 
EdaiManam 
Nurai 
Enjal 
In addition, frequency of micturation and sediments are noted. 
 
NEIKKURI: 
The collected specimen (Urine) is kept open in a glass dish or china clay 
container. It is to be examined under direct sunlight without any shaking of the vessel. 
Then add one drop of gingelly oil without disturbing the specimen and neikkuri was 
noted in direct sunlight and conclude the diagnosis as follows. 
 
CHARACTER OF VATHANEER:  
In „Vaathaneer‟ oil drop lengthens like a Snake 
 
CHARACTER OF PITHANEER:  
In „Pithaneer‟ oil drop spreads like a ring. 
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CHARACTER OF KABANEER: 
In „Kabaneer‟ oil drop spread like a pearl. 
 
CHARACTER OF THONTHANEER: 
Snake in the ring, ring in the snake, snake in the pearl and ring in the pearl are the 
characters of thonthaneer. 
 
PARUVAKALAM: (Season) 
Siddhars have classified a year into 6 seasons each constituting 2 months.  
They are 
1. Kaarkalam              – Avani & Purattasi (Aug15 to Oct15) 
2. Koothirkalam         –  Ippaasi & karthikai (Oct15 to Dec15) 
3. Munpanikalam       –  Margazhi & Thai (Dec15 to Feb15) 
4. Pinpanikalam         –  Masi & Panguni (Feb15 to Apr15) 
5. Elavaenirkalam      –  Sithirai & Vaigasi (Apr15 to Jun15) 
6. Muthuvenilkalam  –  Aani & Aadi (Jun15 to Aug15)  
 
Puzhuvettu   does not related with any seasonal variation. 
 
BODY IMMUNITY (UDAL VANMAI): 
The vanmai is classified into 3 kinds. 
They are: 
1. Iyarkai vanmai 
2. Kala vanmai 
3. Seyarkai vanmai 
 
1. Iyarkai  vanmai : 
Natural   immunity of the body caused by three vital humour right from birth 
onwards. 
 
2. Kala vanmai : 
Development of immunity according to age and environment. 
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3. Seyarkai vanmai : 
Improving the health by intake of nutritients, food materials, activities and 
medicines. 
 
PHYSICAL CONSTITUENTS (UDAL THATHUKKAL) 
 
UDAL THATHUKKAL  -    GENERAL DEFINITION OF EACH TYPE 
Saram                               -    Give strength to body and mind. 
Seneer                        -  Responsible for knowledge, strength, boldness,  
                      healthy complexion 
Oon                          -  Gives structure and shape to body and is  
         responsible for movement of the body 
Kozhuppu                        -  Lubricates the internal organs and helps the organs  
       to work smoothy. 
Enbu                                -  Protects the vital organs and act as basis for  
         movement and maintain body structure. 
Moolai                             -  Present inside the bones and it gives strength and  
           maintains the normal condition of the bone 
Sukilam/Suronitham     -  Responsible for reproductive function of species. 
 
Human body is made up of seven udal kattugal which are important for the 
structure and function of the body. In case of Puzhuvettu, among the seven udal kattugal 
(seven physical constituents) Saram and Seneer  were affected.  
 
நபேத்துயம்: 
1. வயற்று஥ில஬ ய஭ர்ச்ெினலடந்த யாதத்தில஦ தன்஦ில஬ப்஧டுத்த 
வயண்டும் Kazhichal Marunthugal 
2. யன்லந இமந்த உடற்கட்டுகல஭ யன்லந அலடனச்வெய்ப௅ம் 
யலகனில் நபேந்த஭ிக்க வயண்டும். 
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Line of treatment:  
 
      Siddha treatment is not only for complete healing but also prevention and 
rejuvenation. Saint Thiruvalluvar says about physician‟s duty, study the disease, study 
the cause treat subsiding way and do what is proper and effect. 
 
“ வ஥ாய் ஥ாடி வ஥ாய் ப௃தல் ஥ாடி அது தணிக்கும் 
யாய்஥ாடி யாய்ப்஧ச் வெனல்” 
“உற்஫ா஦ ஭வும் ஧ிணின஭வுங் கா஬ப௃ங் 
கற்஫ான் கபேதிச் வெனல்” 
- திபேக்கு஫ள்   
So it is essential to know the disease, the etiology, the nature of patients, severity 
of  the illness, the seasons and the time of occurrence. 
 
Line of treatment is as follows: 
1. Kaappu (Prevention) 
2. Neekkam (Treatment) 
3. Niraivu (Restoration) 
 
1. Kaappu (Prevention) : 
Prevention and cure of the disease are the basic principle of any medical system but 
in our Siddha system prevention is the main aim.  Siddhars have described general 
preventive measures and special measures. Especially in Balavagadam, the preventive 
measures are explained in detail. Prevention of the disease starts from the conception 
and goes on as the conception and goes on as the child grows up in intrauterine life and 
after delivery. Siddhars have dealt elaborately with the diet of pregnant women, her 
habit, the medicine to be taken in every month, her psychological condition and 
surrounding etc.  
Avoid bathing in lake, pond. 
Maintaining  hair hygiene. 
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2. Neekam (Treatment) : 
The aim of Neekam is based on,  
To bring the deranged humours to equilibrium state. 
To treat the patient according to the symptoms by Internal medicine “Silvisha 
Usidham” and Éxternal medicine “Puzhuvettu Thylam” 
Virechanam (Purgation) 
Ulmarunthu (Internal medicine) 
Velimarunthu ( External Medicine ) 
Pathiyam  
 
3. Niraivu (Rejuvenation ) 
Physical, Psychological, social rehabilitation and reassurance of individuals is known 
as Niraivu. 
Rest  
Positive mental attitude 
Life style modification 
Modification in daily activites 
 
Virechanam : 
2-3ml of Mantha ennai with luke warm water was administered at bedtime. 
Before starting the treatment to bring the vitiated vatham to normal. 
 
Internal and External medicine : 
Silvisha Usidham 2-4ml twice daily for 45 days. 
Puzhuvettu Thylam for external application indicated for Puzhuvettu in the text Siddha 
Anubhoga Vaithiya Navaneedha Thirattu. 
 
஧த்தினம் : 
“஧த்தினத்தி஦ாவ஬ ஧஬னுண்டாகும் நபேந்து 
஧த்தினங் வ஧ா஦ால் ஧஬ன் வ஧ாகும் –஧த்தினத்தில் 
஧த்தினவந வயற்஫ிதபேம் ஧ண்டிதர்க்கு ஆத஬ி஦ால் 
஧த்தினவந உத்திவனன்று ஧ார்“ 
- வதலபனர் வயண்஧ா 
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 Diet for alopecia areata   : 
 Non animal sources of protein, like whole grains, beans, nuts and seeds 
 Foods that are high in calcium, such as  soy products, nuts, nut milks, soymilk   
and certain leafy greens 
 Healthy fats like olive oil,  walnuts, flax seed  
 Omega-3 fatty acids, found in , tuna and salmon 
 Fresh fruits and vegetables, as they are high in antioxidants 
 Vitamin B rich foods, like nuts, carrots, lettuce and tomatoes 
 
Different foods that aggravate the condition and therefore should be strictly 
avoided : 
 Animal fat, especially meat 
 Acidic food and other substances that trigger off inflammation 
 Milk and dairy products 
 Sweets and other sugary foods 
 Refined foods, like bakery items 
 Fried, oily and greasy food 
 
PREVENTION METHODS: 
The patients were advised, 
1. Good hair hygiene. 
2. Good Nutrition especially adequate level of iron and vitamins. 
3. Treatment of underlying medical conditions like thyroid disease, anemia and 
hormonal imbalance. 
4. To avoid contaminated food and water 
5. To take highly nutritious diet like vegetables, greens and fruit and do yoga to get 
their immunity developed. 
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3.2. MODERN ASPECT 
 
 
ANATOMY OF THE SKIN- CROSS SECTION OF SKIN 
 
  
The skin is a vital organ that covers the entire outside of the body, forming a 
protective barrier against pathogens and injuries from the environment. The skin is the 
Body‟s largest organ. The color, thickness and texture of skin vary over the body. There 
are two general types of skin .Thin and hairy, which is more prevalent on the body and 
thick and hairless, which is found on parts of the body that are used heavily and endure a 
large amount of friction, like the palms of the hands or the soles of the feet Basically, the 
skin is comprised of two layers that cover a third fatty layer. These three layers differ in 
function, thickness and strength. The outer layer is called the epidermis. It is a tough 
protective layer that contains the melanin – producing melanocytes. The second layer is 
called the dermis. It contains nerve endings, sweat glands, oil glands, and hair follicles. 
Under these two skin layers is a fatty layer of subcutaneous tissue, known as the   
subcutis or hypodermis. 
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PARTS OF THE SKIN: 
 The epidermis 
  Dermis 
  Hypodermis /subcutaneous tissue 
 
EPIDERMIS: 
The epidermis is the most superficial layer of the skin and provides the first 
barrier of production from the invasion of foreign substances into the body. The principal 
cell of the epidermis is called a keratinocyte. 
 
Layer of the epidermis: 
Stratum corneum /corneal layer /horney layer 
Stratum lucidum 
Stratum granulosum/granular layer 
Stratum Spinosum 
Stratum basalis /basal layer 
 
EPIDERMAL APPENDAGES: 
 
HAIR FOLLICLE: 
There are 3-5 million hair follicles, epidermal invaginations that develop during 
the second trimester. They occur throughout the skin, with the exception of palms, 
soles and parts of the genitalia (glabrous skin). 
 
The highest density of hair follicle is on the scalp (500-1000/cm square). 
Newborn are covered with fine „lanugo‟ hairs, which are usually non-pigmented and 
lack a central medulla, these are subsequently replaced by vellus hair, which is 
similar but more likely to be pigmented. 
 
By contrast, scalp hair becomes terminal hair, which is thicker with a central 
medulla, is usually pigmented and grows longer. At puberty, vellus hair is 
hormonally sensitive regions, such as the axillary and genital area, become terminal. 
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Human hairs grow in a cycle with three phases: 
1. Anagen (Active hair growth) 
2. Catagen (Transitional Phase) 
3. Telogen (Resting Phase) 
 
            The duration of each phase varies by site. On the scalp, Anagen lasts several 
years, catagen a few days and telogen around 3months.The length of hair at different 
sites reflects the differing lengths of anagen. 
 
Hair Physiology : 
             There are three types of hair 
1. Lanugo Hair 
2. Vellus Hair 
3. Terminal Hair                         
 
Lanugo hair – Long, unmedullated hair seen in utero and are shed during the end 
of pregnancy and the first several months postpartum. 
  
Vellus hair – Short, non-pigmented hair produced by follicles (Intermediate hair) 
that penetrate only into the papillary dermis, 
 
Terminal hair – Terminal hair are produced by follicles that penetrate into the 
reticular dermis and are usually medullated and are wider than the inner root sheath of 
the follicle that produces them. Hair on the scalp and bread area a examples of terminal 
hair. In the inherited types of balding, some terminal hair are lost and vellus hair are seen 
instead. 
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CYCLES: 
                       
                     
 
 
 
 
 
 
 
 
 
Anagen (Growth) Phase – About 85% to 95% of scalp hair are in this phase. 
Catagen (Regressive) Phase - About 1% of scalp hair are in this phase. 
Telogen (Resting) Phase – About 10% to 15% of scalp hair are in this phase. 
 
                The length of the anagen phase determines the length of the hair. The anagen 
for human scalp hair is usually between 2 and 6 years and the hair on the scalp grows 
about 1cm per month therefore, some people can never have very long hair on the scalp 
even if they never cut their hair. 
 
Growth phase of hair on other body parts are much shorter than on the scalp. It is 
normal to lose between 50 and 100 scalp hair per day. Plucking the resting hair from 
follicles that have already entered anagen can advanced the onset of the hair cycle. The 
telogen phase is the period between the completion of follicular regression (Catagen) and 
the onset of the next anagen phase. 
 
                On the human scalp the telogen phase lasts about 2 to 4 months. The catagen 
phase on the human scalp lasts 2 to 4 weeks. 
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FUNCTIONS OF HAIR: 
1. Cosmetic 
2. Hair screens entry of irritants to nose 
3. Protect Scalp from sunrays 
4. Shields the eyes 
5. Helps in perception of tactile stimuli 
 
ALOPECIA AREATA 
       Alopecia areata is a common skin condition characterized by localized hair loss, 
frequently in children. Both sexes are equally affected. Alopecia areata may be 
associated with the atopic state and autoimmune disorders such as vitiligo, familial 
multiendocrine syndrome, thyroid disease (Hashimotos disease), SLE, pernicious 
anemia, myasthina gravis, ulcerative colitis and lichen planus.  
 
             Prevalance is estimated at approximately 0.2% of the population. Incidence of 
this disease is 17.2/100,000 population. There is a history of familial occurrence 10-20% 
of the affected individuals .It affect all age group. The first episode usually occurs in 
patients less than 25 years of age. 
 
            Most children develop discoid areas of alopecia in the scalp with peripheral 
exclamation hairs, and these areas regrow hair normally in due course.In some 
children,however,particularly those with an ophiasis  form distribution of hair loss 
(invoving the temples and occipital region), the condition is progressive to become total, 
and regrowth is much less likely.There are also nail changes with fine pitting and 
horizontal depressions known as Beau‟s lines.Although Alopecia areata is not a life 
threatening condition it is obviously distressing for children for children and parents
9
. 
 
Types of alopecia areata 
1. Alopecia  totalis (Hair loss in whole scalp) 
2. Alopecia universalis ( Whole body) 
3. Ophiasis (Occipito-parieto-temporal) 
4. Sisaipho 
5. Diffuse 
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 Alopecia areata (AA): 
Alopecia areata is an autoimmune condition which causes patchy hair loss.It can 
result in a single patch or extensive patchy hair loss 
 
 Alopecia   Totalis (AT): 
Alopecia totalis is a more advanced form of alopecia areata which results in total 
loss of all hair on the scalp. 
 
 Alopecia Universalis (AU): 
Alopecia universalisis the most advanced form of alopecia areata which results in 
total loss of all hair on the body, including eyelashes and eyebrows. 
 
 Scarring Alopecia  (Cicatricial Alopecia) : 
Scarring alopecia refers to a group of rare disorder which causes permanent hair 
loss. It is caused by any inflammatory processes which causes permanent damage 
to hair follicles.  
 
 OPHIASIS: 
It is a form of alopecia areata characterized by the loss of hair in the shape 
of a wave at the circumference of the head.‟Ophis‟ which is a greek word 
snake,because of the apparent similarity  to a snake –shape and the pattern of hair 
loss.Sisaipho is the reverse spelling of ophiasis.It is also called „Ophiasis 
inversus”.      
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ETIOLOGY: 
1. Genetic 
2. Autoimmunity 
3. Infection 
4. Emotional stress 
                                                                                                                                       
CLINICAL FEATURES: 
1. Sudden appearance of one or more round or oval well defined patches of hair 
loss. 
2. The hair loss may occur overnight or over a period of several days. 
3. Scattered long hairs within bald area. 
4. Initial loss may be diffuse and the patches of baldness may be apparent only after 
1 or 2 weeks. 
5. Exclamation – mark hairs indicates progression of the patch (Active disease). 
6. Dystrophic nail changes occurs (pits, longitudinal ridging and thickening). 
7. Cataracts or lens opacification. 
8.  Associated with autoimmune diseases such as Hashimoto thyroiditis,Addison 
disease,Pernicious anemia,ulcerative colitis,myasthenia gravis, collagen vascular 
disease and vitiligo. 
 
Indicators of poor prognosis are: 
 Atopy 
 Presence of other autoimmune diseases 
 Family history of Alopecia areata 
 Early age of onset  
 Extensive hair loss 
 Ophiasis 
 Nail dystropy 
 
ETIOPATHOGENISIS: 
         The exact etiology of alopecia areata remains unknown, but there are various 
postulations. It is generally believed to be an autoimmune disease. 
 
25 
 
          CD4 and T lymphocytes mediate the perifollicular immune against the antigen 
which may be present in the follicular keratinocyte, melanocyte or dermal papilla, by 
triggering a cascade of events via cytokine production. Cytokines such as Interferon 
gamma, Interleukin – 2 and Interleukin – 1β, have been found in the affected area of the 
scalp. 
         Calcitonin gene related peptide, which has potent anti-inflammatory actions and 
substance P, which is capable of including hair growth, are found to be decreased in the 
scalp of alopecia areata patients. 
 
HISTOPATHOLOGY: 
1. Perivascular, peribulbar and outer root sheath infiltrate and follicular dystrophy 
(Swarm of bees appearance) 
2. Lymphocytic and eosinophilic inflammatory infiltrate 
 
DIFFERENTIAL DIAGNOSIS : 
1. Tinea capitis 
2. Traction alopecia 
3. Trichotillomania 
4. Loose anagen syndrome 
5. Telogen effluvium 
6. Androgenetic alopecia 
 
TINEA CAPTIS:  
 Scalling or inflammation of the scalp usually present 
 Black dot hairs may be observed 
 Regional lymphadenopathy may be present 
 Fungal culture or potassium hydroxide preparation would be positive 
 
TRACTION ALOPECIA: 
 Symmetrical bilateral involvement typical 
 Thinning or complete hair loss, especially around hairline or in areas 
where hair is parted Hair styling usually suggestive with tight braids and 
heavy hair ornaments 
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TRICHOTILLOMANIA 
 Usually causes localized hair loss  
 Irregularly shaped area of incomplete 
 Hair of differing lengths in affected area 
 
LOOSE ANAGEN SYNDROME 
 Typically long history of diffusely thin and lusterless hair 
 Hair grows slowly; History of no haircuts common 
 Hair mount of easily extracted hairs confirms the diagnosis. 
 
TELOGEN EFFUVUM 
 Usually diffuse thinning without areas of complete hair loss 
 Typically associated with preceding physical trauma/ illness believed to 
trigger  conversion from anagen to telogen phase of hair 
 Self-limited; gradual improvement within months 
 
ANDROGENETIC ALOPECIA 
 Not typically seen in younger children 
 Classic distribution; symmetrical over vertex and frontal hair line 
 May be associated with sign on hyper androgenic  
 No associated nail changes. 
 
INVESTIGATIONAL AGENTS 
 Cytokines 
 Antibodies 
 Gene therapy 
 Biologic therapy 
 Adjunctive agents 
 
DIAGNOSIS: 
 Usually a clinical one, based on the typical finding 
 In some patient, there may be associated loss of eyebrows and lashes 
characteristic nail changes. 
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 Skin biopsy rarely necessary to confirm the diagnosis, finding includes 
perifollicular lymphocytic infiltration. 
 
Management for Alopecia Areata:  
                 The treatment available for Alopecia areata at present can only control the 
disease, but not curative.Local treatment may help the treated areas but do not prevent 
further spread.The first and most important step in the management of alopecia areata is 
to give psychological support and counseling.A change of hair-style,caps,hats,head 
bands and wigs may be required for adequate camouflage. 
 
Current Agents 
 Corticosteroids 
 Topical 
 Intralesional 
 Systemic 
 PUVA(Psoralen Ultraviolet A) 
 Minoxidil 
 Topical sensitizers 
 Anthralin 
 Imiquimod 
 
PROGNOSIS: 
 Prognosis is difficult to predict and extremely variable 
 Many children with isolated episodes of localized patchy hair loss will have 
spontaneously hair regrowth without therapy 
 Children with rapid and extensive hair loss, especially when progressing to 
complete loss, usually respond poorly to therapy. 
 
RESOURCES FOR FAMILIES: 
 National Alopecia Areata Foundation:  
 Provides information, support and resources for patients and families10. 
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3.3. DRUG REVIEW 
1.஌஬ம்  
Taxonomical classification:  
Kingdom                                 : Plantae 
Phylum                                   : Angiosperms 
Order                                       : Zingiberales 
Family                                     : Gingiberaceae 
Genus                                      : Elettaria 
Species                                    : Elettaria cardamomum 
 
Botanical name         : Elettaria cardamomum 
Family                                     :  Zingiberaceae 
Other  name                             : Aanji,Korangam,Thudi 
Eng                                          : Cardamom                   
 Hindi                                      :  Chhoti elachi             
 Tel                                          :  Elakulu 
Mal                                          :  Elatlari                          
Kan                                         :  Elakki 
Habitat                              : Cultivated for its fruit in many parts of western and  
    southern india. 
Parts Used                              :  Dried ripe seeds ;Oil from fruits 
Suvai                                      :  Kaarppu                  
Thanmai                                 :  Veppam                   
 Pirivu                                   : Kaarppu 
 
Action : 
Powerful aromatic,  Stimulant, Carminative, Stomachic and Diuretic 
11
. 
 
These properties are due to the essential oil contained in the seeds. 
வதாண்லட யாய்கவுள் தாலுகு தங்க஭ில் 
 வதான்றும் வ஥ானதி ொபம்஧ன் வநகத்தால் 
உண்லட வ஧ால்஋ழுங் கட்டி கிரிச்ெபம் 
 உமல஬ யாந்தி ெி஬ந்தி யிரஞ்சுபம் 
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஧ண்லட வயக்லக யிதாகவ஥ாய் காெப௃ம் 
 ஧ாழுஞ் வொநப் ஧ிணியிந்து ஥ட்டப௃ம் 
அண்லட னீல஭யன் ஧ித்தம் இலயக்வகல்஬ாம் 
 ஆ஬ நாங்கநழ் ஌஬ நபேந்தவத 
-வதலபனர் குணயாகடம்11 
Chemical Constituent: 
Fixed oil, Essential oil, Volatile oil of the seeds- active principle 4 to 8 p.c and 
„contains considerable amount of  Terpinyl acetate, cinole, free terpinol and limonene 12 
α-pinenes, β-pinenes, camphene, P-Cymene, terpinene, α-terpineol and α-humulene 
isolated from essential oil of fruits and leaves 
13
 . 
 
Therapeutic uses: 
Abdominal pain, cough, Thirst, Diarrhoea, Oliguria, Sinusitis, Skin disease and 
Indigestion  
 
Scientific review 
1. Immunomodulator activity : 
In vitro investigation of the potential immunomodulatory activities of cardamom. 
Aqueous extracts of cardamom significantly enhance spenocyte proliferation in a dose – 
dependent synergistic fashion. ELISA experiment reveal cardamom significantly 
enhance and suppress respectively, T–Helper (Th-1) cytokine release by splenocytes. 
Conversely, T–Helper (Th-2) cytokine release by splenocytes is significantly suppressed 
and enhanced by cardamom respectively. cardamom constituents can be used as potential 
therapeutic tools to regulate inflammatory response
14
.   
 
2. Immunomodulator activity : 
Cardamom – essential oil is popular in skin care. Its effect on 17 protien 
biomarkers closely related to inflammation, immune responses and tissue remodeling 
using a dermal fibroblast cell culture system designed to model chronic inflammation. Its 
major active component is Eucalptol.CEO (Cardamom essential oil) – induced inhibition 
of these genes and pathway supports its anti-inflammatory and immunomodulatory 
properties.
15
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3. Antimicrobial, Antifungal Activity and Anti inflammatory activity. 
The volatile oil of the fruit of Elettaria cardamom showed significant 
antimicrobial activity against pathogenic bacterial and fungal strain. Cardamom essential 
oil had inhibitory effect against fungus growth and anti-inflammatory activity 
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2. ஋ள் 
Taxonomical classification:  
Kingdom                              : Plantae 
Phylum                                 : Angiosperms 
Order                                    : Lamiales 
Family                                   : Pedaliaceae 
Genus                                    : Sesamum  
Species                                  : Sesamum indicum 
 
Botanical name        :  Sesamum indicum  
Family                                :   Pedaliaceae  
Other name                         :  Thilam 
Eng                                     :  Gingeli oil plant, gingilly, sesame                 
Hindi                                  :  Thil                  
Tel                                      :  Nuvulu 
Mal                                     :  Karuella                    
San                                      :  Thilam 
Habitat                                :  Annual plant 
 
Varities : Sesamum seeds are found –Black, White and red or brown leaves, flowers. 
Parts Used : Leaves, Flower, Seeds and the fixed oil expressed from the seeds 
Suvai   :  Inippu                   
Thanmai     :  Veppam                       
 Pirivu       :  Inippu 
 
Action : 
             Seeds: Laxative, Emollient and demulcent, Diuretic, Nourishing, emmenagogue, 
lactogogue. 
Oil action : Demulcent, Laxative, Nutritive, Emollient 
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   ஋ள்ல௃நபேந் லதக்வகடுக்கும் ஋஫஦஬ாந் திண்லநதபேம் 
  உள்஭ில஬லனச் வெர்க்கும் உதிபத்லத-தள்ல௃நிபே 
      கண்ணுக் வகா஭ிவகாடுக்குங் காெப௃ண்டாம் ஧ித்தப௃நாம் 
  ஧ண்ணுக் கிடர்புரிப௅ம் ஧ார். 
-அகத்தினர் குணயாகடம் 
Chemical Constituent : 
Diosgenin, β – sitosterol, lanosterol, solasonine, solamargine and solasodine 17   
Seed contains -protein,carbohydrate,mucilage,woody fibre,ash, fixed oil. 
 
Oil contains  -      Stearin, palminitin, myristin, a crystalline substance sesamine, a phenol  
                        compound sesamol Vit –E, Phytosterol 
 
Seeds contain fixed oil 50 to 60 p.c 
18
 
                                Moisture                                    Oil 
Black Til               2.0 to5.2 p.c                                 44.6 to 56.9 p.c 
Red Til                   -                                                   45.7 to 55.5 p.c 
White Til              2.0 to 4.4 p.c                                 44.9  to 58.2 p.c 
 
Therapeutic uses: 
Eye and ear releated disease, Skin disease, ulcer, Burns and cough. 
 
Scientific review 
 
1. Anti Inflammatory Activity 
Anti inflammatory activity of sesame oil and sesamin – Leucocyte migration were 
also reduced by sesame oil and sesamin
19. 
 
2. Immunomodulating activity 
The mechanism of sesame oil in ameliorating experimental autoimmune 
encephalomyelitis in C57BL / 6 mice . Sesame oil reducing  IFN – gamma secretion.20  
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3. Piper longum  - திப்஧ி஬ி 
Taxonomical classification:  
Kingdom                                 : Plantae 
Phylum                                   : Angiosperms 
Order                                       : Microembryeae 
Family                                     : Piperaceae 
Genus                                      : Piper  
Species                                    : Piper longum 
 
Botanical Name                      : Piper longum   
Family                                     : Piperaceae 
Other name : Aargadhi, unsaram, ulavainaasi, kaaman, kudari, kolagam, koli,  
  kozhaiyarukki, saram, saadi, thulavi,  maagadhi, sondi, thandoli, kanam,    
  kalini, baanam, pippili, vaitheyki, ambu, aadhimarundhu. 
Eng                                         :  Long pepper                         
Tel                                           :  Pippilu 
Mal                                          : Thippilli                  
 Kan                                        :  Hippili 
Parts Used                               :  Fruit,dried spikes and roots 
Suvai                                       :  Inippu                  
Thanmai                                 : Veppam                      
Pirivu                                      : Inippu 
Action                                     : Stimulant, Carminative 
Varieties                                 : Arisi thippili and Yanai thippili 
Habitat                                    : Climber       
 
இபேநல் குன்நம் இலபப்பு கனப்஧ிணி 
ஈல஭ ஧ாண்டு ெந்னாெம் அவபாெகம் 
வ஧ாபேநல் ஊலத ெிபப்஧ிணி ப௄ர்ச்லெவ஥ாய் 
பூரிக் குஞ்ெ஬  வதாடம் ஧ீ஬ிகப௃ம் 
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யபேந ஬ப்வ஧பேக் வகாடு நவகாதபம் 
யாதம் ஆதிப௃த் வதாடஞ் சுபங்கு஭ிர் 
வ஧பேநால஬ப்புரி வநகப் ஧ிடகப௃ம் 
வ஧பேந் திப்஧ி஬ிப் வ஧பங்குலபக்கவய. 
                            -வதலபனர் குணயாகடம். 
 
It cures cough, ulcer, bronchial asthma, kapha diseases, anaemia, headache, 
delirium, sinusitis and throat pain. 
 
Chemical Constituent:  
          Two new piperidine alkaloids–pipernonaline and Piperundecalidine – isolated 
from fruits and their structures determined 
21
. 
          Volatile oil, resin, starch, gum, fatty oil, Inorganic matter and an alkaloid, 
Piperine, Rutin,β-caryophyllene, piperyline, piperoleines, piperamine, sabinene, 
chavicin, pinene, phellandrene, pentadecane, β- bisabolene, linalool and limonene. 
 
Therapeutic uses: 
           Cough, ulcer, asthma, kabha disease, anemia, lethargy, flatulence, headache, 
delirium, sinusitis, throat disease, ear, nose, eye related disease, worm infestation. 
 
Scientific review 
1. Anti inflammatory property: 
Piper extracts and piperine possess inhibitory activities on prostaglandin and 
leukotrienes COX-1 inhibitory effect and thus exhibit anti-inflammatory activity.
22 
 
 
    2.  Immunomodulator Activity : 
Alcoholic extract of the fruits of the plant Piper longum and its Component 
Piperine was studied  their immunomodulatory activity Piperinic acid moderated the 
pro inflammatory mediators and cytokines in the experiment, decreases of 
lymphocytes cytokine levels in sensitized Balb/c mice .
23
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4. வ஧னத்தி 
Taxonomical classification:  
Kingdom                                : Plantae 
Phylum                                   : Angiosperms 
Order                                     :  Rosids 
Family                                    : Moraceae 
Genus                                     : Ficus  
Species                                    : Ficus hispida 
 
Botanical Name       : Ficus hispida   
Family                              : Moraceae 
Other name                     : Pe-allippayam,kattu- atthi, pe-atthi, pe- attiss, pechi, pethi 
Eng                                  :  Fig tree                 
Hindi                                 : Katgular                  
Tel                                     :  Atti - pandhlu 
Parts Used                         :  Leaves,Bark and fruit 
Suvai                         :  Thuvarppu                    
Thanmai                         :  Thatppam                     
Pirivu                             :  Inippu 
Action        :  Bark-emetic, Laxative Fruit-Colling, Astringent, Sour 
Habitat                             :  Tree 
 
Chemical Constituent: 
Bergapten, Psoralen, β –Amyrin and β– sitosterol 24 Hispidine,  
Phenanthraindolizidines 
25 
n – triacontanyl, Gluanol acetates26 ,Tannin,wax,a caoutchouc 
– like substance and saponin. 
 
Therapeutic uses: 
             Bleeding piles, diarrhoea, leucorrhoea, menorragia, diabetic ulcer and arthritis. 
 
Scientific review 
1. Anti – inflammatory  property 
    Leaves extract of  Ficus hispida leaves  against cargeenan induced paw edema 
in rats.
27
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5.Amanakk-kenny 
Taxonomical classification:  
     Kingdom                             : Plantae 
     Phylum                                : Angiosperms 
     Order                                   : Euphorbiales 
     Family                                  : Euphorbiaceae 
     Genus                                   : Ricinus 
     Species                                  : Ricinus communis 
 
Botanical Name    :  Ricinus communis  
Family          :  Euphorbiaceae 
Other name          :  yerandam,Sithiram,Thalarubam 
Eng                :  Castor oil                  
Hindi                                 :  Arand-kat                 
Tel                                     : Amudam 
Mal                                    : Kottenna                            
Kan                                    :  Haralenne 
San                                     :  Yeranda-tailam 
Habitat                               :  Two types 
 
Small tree – 1. Chittamanakku 
                    2. Peramanakku 
                    3. Chevvamanakku  (Ricinus tanarius) 
 
Herb        -   1. Kaatamakku 
                    2. Yeliyamanakku 
 
Parts Used            :   Leaves, Root and Seed. 
Suvai                            :   Kaippu                    
Thanmai                      :   Veppam                 
Pirivu                       :   Karppu 
Action               :   Galactagogue, Anti-vatha, Laxative and Emollient 
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Chemical Constituent : 
Ricin , Ricinoleic acid, Fatty acid , Linoleic acid, oleic acid, Palmitic acid, Stearic 
acid,  linolenic acid and triacylglycerols. 
                                                            Moisture:                                         Oil: 
                                                                  p.c                                               p.c 
Castor (general)                                   2.97 to 6.97                                 38.57 to 57.40 
Castor (Big variety)                             2.97 to 6.25                                 46.63 to 55.43 
Castor (Small variety)                         3.17 to 6.06                                 43.39 to 57.40 
Castor (Without awns)                        4.24 to 5.20                                 48.28 to 51.86 
 
            வ஧பண்டத்துவ஥ய் வனன்஧து டற்வகாடு 
ெபீண்டத்தணி வெய்திடு ஥ிெவந. 
                             - வதலபனர்  
ஆநணக்கு வ஥ய்னால் ஥஬ப௃ண்டாம் னாயர்க்கும் 
பூநணக்கு வந஦ி புரிகுமவ஬ – யாய்நணக்கக் 
வகாள்஭ில் யனிறுயிடுங் வகாபப௃ள்஭ யாப௅யறும் 
உள்஭ில்யபே குன்நம்வ஧ா வநாது. 
  
அம்வ஧ா஦ி஫ ப௃ம்யிந்து நாங்குட஬ி வ஦ற்஫நறும் 
஍ம்வ஧ா஫ிச் சூவடரிவு நாறுங்காண் –அம்புயினிற்  
஧ாநணக்கு நின்஧வநாமிப் ஧ாயாய் ! ஥஬ஞ்வெ஫ிந்த 
ஆநணக்கு வ஥ய்லன அபேந்து. 
 
ஆந஦க் வகண்வணய் தன்ல஦ னணி஥ி஬ ந஫ினக் வகண்நின் 
பூநணச் ெந்துவதாறும் வ஧ாபேந்தின யாதம் வ஧ாக்கும் 
தநீந்தந் தானும் வ஧ாக்குந் திகழ்வுடன் யிலபவு ப௃ண்டாம் 
தநீ஦க் குட஬ில் யாதஞ் வெர்குட வ஬ற்஫ம் வ஧ாவந. 
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Therapeutic uses: 
1. Castor oil is one of the cheapest, simplest and  most important and useful purgatives 
in all delicate conditions for children and old people. 
2. Chronic articular rheumatism 
3. Sinusitis, Sore nipples 
4. Colicky pain 
 
6. Kungiliyam 
Taxonomical classification: 
Kingdom   :  Plantae 
Phylum      :  Angiosperms 
Order           :  Malvales 
Family        :  Dipterocarpaceae 
Genus         : Shorea 
Species       : Shorea robusta 
Botanical Name                  :  Shorea robusta     
 Family                               :  Dipterocarpacea 
Other name   :  Kungiliyam, kungiligam, saruvrasam, gugulu, kukil 
Eng                                     :  Sal tree, Indian Damar                 
Hindi                                  :  Dhuna, Damar               
Tel                                      :  gugilamu 
Mal                                     :  Kungiliyam                  
 San                                    :  Guggilam                  
 Arab                                  : qaaguahar 
Parts Used                          :  Resin 
Suvai                                  :  Kaippu                   
Thanmai                             :  Veppam                    
 Pirivu                                : Karppu 
Habitat                               : Tree 
 
Types : 
1. White 
2. Red 
Action                                         : Stimulant, Expectorant, Diuretic 
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Chemical Constituent   :  
Chalcone,-4-hydroxychalcone-4-O-β-`D-glucopyranoside 28. S. robusta resin has 
been reported to contain several mono-, sesqui- and tri-terpenoids includes ursolic acid, 
tri and tetra hydroxy ursenoic acid, asiatic acid, α and β-amyrin, α –amyrenone, 
mangiferonic acid, benthamic acid and uvaol
29
. 
 
வயள்ல஭க் குங்கி஬ினம் (ெபேயபெம்) 
      வயள்ல஭ ன஭ித்த யிபண஥ா ஧ிக்கந஬த் 
வதாள்ல஭யிப ணம்வநகந் வதாற்றுகினும் –உள்வ஭ 
   யபேயபெல஦வநற்புண் யரினுஞ் சுவயதச் 
ெபேயபெ வநற்஧மிலனச் ொற்று. 
                            -வதலபனர் குணயாகடம். 
Therapeutic uses : 
 Menorrhage, Leucorrhoea, Ulcer, Abscess 
 Internal hemorrhoids 
 Ear, Nose, Throat Disease 
 Syphilitic ulcer 
 Dysentry, urticaria, Arthritis 
 Disease of nail the powdered resin is mixed with sugar and given for diarrhoea in 
children. 
 The powdered resin along with milk is taken as an alternative. 
 It is used for fumigating the rooms of ill people.      
 It is used as an ointment for wound as an ingredient of ointments for skin diseases 
and in ear troubles. 
 The resin obtained from the plant is considered as an astringent and is used in 
dysentery and bleeding piles. 
 It is also given in gonorrhea and for delayed digestion.  
 
Scientific review 
1. Anti Inflammatory activity : 
2. Ethonolic extract of Shorea robusta resin has anti inflammatory activity- 
carrageen induced paw edema and sub –acute by cotton pellet- induced granuloma in 
male Wistar rats.
30
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7. AVURI 
Taxonomical classification: 
Kingdom :  Plantae 
Phylum    :  Angiosperms 
Order         :  Fabales 
Family      :  Fabaceae 
Genus       : Indigofera 
Species     : Indigofera tinctoria 
  
Botanical name                    :  Indigofera tinctoria    
Family                                  :  Fabaceae 
Other name                           :   Neelam, nilam, Aviri, Avari 
Eng                                        :   True indigo, Dyer‟s       
 Hindi                                    :   Sind           
Tel                                         :   Aviri, Neeichettu, neli 
San                                        :   Neela, Neelinee, Nililea 
Parts Used                             :  Leaf, Root, Plant and Expressed juice - Indigo 
Suvai                                     :  Kaippu                  
 Thanmai                               :  Veppam                     
 Pirivu                                    :  Kaarppu 
Habitat                                   :  Shrub 
Action             :  Stimulant, Alternative, deobstruent, Germicide,  
                                       Antiperiodic and Purgative Indigo is antiseptic  
                                    and astringent. 
உரின஬வு ரித்தலமத்தான் ஏது ஧திவ஦ண் 
அரின஥ஞ்லெத் தின்஫யர்க்கும் ஆகும் –வதரியரின 
யாதவயப்பு காநால஬ லநந்தர் குறுநாந்தஞ் 
ென்஦ி ஧திப௄ன்றுஞ் ெந்வதாடித்த யாதப௃தல் 
உன்னு யிடக்கடிப௅ம் ஏடுங்காண்-நின்னுங் 
கவுரி஥ி஫ம் உண்டாகும் காெி஦ிப௅ள் ஥ல்஬ 
அவுரினில஬ தன்஦ால் அ஫ி. 
                            -அகத்தினர் குணயாகடம். 
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Chemical Constituent: 
Indican (Glycoside), Indigotin or Indigo-blue, Indicom, Indigotine, indirubin and 
Glactomannan. 
 
Therapeutic uses : 
 Amtidote, Valisuram, Mantham, Jaundice, Delirium 
 Stomach Ulcer, Leucorrhoea 
 Arthritis 
 Skin Disease 
 
Scientific review 
 
1. Immunomodulatory  activity  
In vitro study of Indigofera tinctoria leaf extract - macrophage response and 
lymphocyte proliferation 
31
  
 
2. Effect  of  UV – B radiation on biochemical and anti oxidant defence system in 
Indigofera tinctoria 
Indigofera tinctoria is resistant to UV -B radiation damage and the possible 
negative effect of additional UV-B radiation on the growth of seedling may have been 
effectively balanced by the UV-B radiation stress through increase in UV-B absorbing 
compound and antioxidant enzymes.
32 
 
3. Hair Growth Promoting activity : 
Ethonol extract of Indigofera tinctoria Linn for their effect on promoting hair 
growth in albino wistar rats.
33
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INRGREDIENTS OF TRIAL DRUG 
SILVISHA USIDHAM 
 
 
 
                      
   Gingelly Oil                                                                  Ficus hispida 
 
 
Eleteria cardamomum                                                            Piper longum                    
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PUZHUVETTU THYLAM 
 
  
 
Shorea robusta                                                                       Castor oil 
                        
 
 
                                  
 
                                                  
 
 
 
 
 
 
Indigofera tinctoria 
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       PREPARED MEDICINE 
SILVISHA USIDHAM (INTERNAL) 
 
 
 
 
 
                                
 
 
 
 
 
 
PUZHUVETTU THYLAM (EXTERNAL) 
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4. MATERIALS AND METHODS 
   
Puzhuvettu is one of the commonest skin conditions in children. It was proposed 
to study about the disease. A protocol was prepared and submitted before IEC of 
National Institute of Siddha. After obtaining IEC approval from the committee the 
clinical study on Puzhuvettu (alopecia areata) in children and the drug of choice was 
Silvisha Usidham (Internal) and Puzhuvettu Thylam (External) was carried out as per the 
protocol. The IEC approval number and date is NIS/IEC/2016/11-20/14.10.2016. 
 
The ingredients for preparation of experimental formulation Silvisha Usidham 
and Puzhuvettu thylam was purchased from a well reputed country shop and raw drugs 
were authenticated by Herbal botanist. The medicine was prepared in Gunapadam lab of 
national Institute of Siddha after proper purification.  
 
4.1 PREPARATION OF MEDICINE: 
 
Ingredients of Silvisha Usidham:                      
                          1. Gingelly oil (Sesame indicum)            - 40 palam (1400gm) 
                          2. Peyathi saru (Ficus hispida)                 -80 palam (2800gms) 
                          3. Elarisithool (Elettaria cardamomum)   -1 palam (35gms) 
                          4. Arisithippili (Piper longum)                 -1 palam (35gms) 
 
Method of Purification: 
 
Peyathi          : Remove petiole and vein of the leaves 
Elarisithool   : Fry to the extent that the contents become golden color 
Arisithippili : Fruit of Piper longum was soaked in lemon juice and it was dried in  
                        sunlight until the juice gets evaporated. Then it was fried well 
 
Method of preparation: 
The above said elarisithool and arisithippili powder mixed with peyathi juice 
together combined with gingelly oil and heated till the waxy consistency is obtained. 
Indication:   Puzhuvettu 
7
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Ingredients of Puzhuvettu Thylam : 
  1. Castor oil (Riccinus comminus)     - 5 Palam (175gm) 
            2. Venkungiliyam (Shorea robusta)    - ¼ Palam (8.75gm) 
            3. Avuri leaf (Indigofera tinctoria)      - 5 Palam (175gm) 
 
Method of Purification: 
1. Venkungiliyam : Resin of Shorea robusta was boiled with tender coconut and   
                           then dried 
2. Avuri                 : Whole plant wash with clean water 
 
Method of Preparation:   
Take avuri paste and venkungiliyam powder in equal quantity, then mixed with 
castor oil afterwards boiled it well till it reaches waxy consistency. 
 
Indication: External application for Puzhuvettu.
7
 
              
4.2 PRECLINICAL SAFETY STUDIES: 
A. Physicochemical Analysis 
B. Biochemical Analysis 
C. Acute Toxicity Study 
D. Phytochemical Analysis 
E. Quantitative  Analysis 
F. Pharmacological Activity 
 
A) PHYSICOCHEMICAL  ANALYSIS OF THE SILVISHA USIDHAM 
 
Physicochemical evaluation 
Determination of specific gravity  
Fill the dry sp. gravity bottle with prepared samples in such a manner to prevent 
entrapment of air bubbles after removing the cap of side arm. Insert the stopper, immerse 
in water bath at 50
O
C and hold for 30 min.  Carefully wipe off any substance that has 
come out of the capillary opening. Remove the bottle from the bath, clean and dry it 
thoroughly. Remove the cap of the side and quickly weigh. Calculate the weight 
difference between the sample and reference standard. 
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Determination of Iodine value  
About 20 gm of test sample was transferred into Iodine flask. To which 10 ml of 
chloroform was added and warmed slightly and cooled for 10 minutes. Followed by this 
about 25 ml of Wiji‟s solution was added in the same flask and shaken well. The flask 
was allowed to stand for 30mins and refrigerated for an hour. T About10 ml of KI 
solution was added to this and titrated against 0.1 N Sodium thiosulphate solutions until 
the appearance of yellow color. 1 ml of starch indicator was added and again titrated 
against the sodium thiosulphate solution from the burette. Disappearance of blue colour 
indicates end point. Repeat the above procedure without taking sample and note the 
corresponding reading for blank titration. 
 
Determination of saponification value  
 
About 2 gm of test sample was transferred into the round bottomed flask. To this 
about 20 ml of 0.5 N alcoholic KOH solutions was added to the round bottomed flask. 
Repeat the same procedure without taking the sample for blank titration. Reflux both 
sample and blank round bottomed flasks for 1 hour. After reflux, allow both the round 
bottomed flasks to cool. Titrate the samples using 0.5 N HCl with phenolphthalein 
indicator. The disappearance of pink indicates the end point.  
 
Determination of Viscosity value  
 
Viscosity determination were been carried out using Ostwald viscometers. 
Measurement of viscosity involves the determination of the time required for a given 
volume of liquid to flow through a capillary. The liquid is added to the viscometer, 
pulled into the upper reservoir by suction, and then allowed to drain by gravity back into 
the lower reservoir. The time that it takes for the liquid to pass between two etched 
marks, one above and one bellow the upper reservoir, is measured. 
 
Determination of Refractive Index 
 
Determination of RL was carried out using Refractometer. 
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Determination of Weight per ml 
Weight per ml was determined using the comparative weight calibration method, 
in which the weight of 1ml of the base of the formulation was calculated and then weight 
of 1 ml of finished formulation were been calculated. The difference between weight 
variations of the base with respect to finished formulation calculated as an index of 
weight per ml. 
 
Determination of pH 
Sample being liquid in nature the direct litmus evaluation method was adopted to 
check the pH of the sample.  
 
Acid Value 
Accurately 5 g of test sample was weighed and transferred into a 250 mL conical 
flask. To this, a 50 mL of neutralized alcohol solution was added. This mixture was 
heated for 10 min by heating mantle. Afterwards, the solution was taken out after 10 min 
and 1 or 2 drops of phenolphthalein indicator was added. This solution was titrated 
against KOH solution from the burette. The appearance of pink color indicated the end 
point. The volume of consumed KOH solution was determined and the titration of test 
sample was carried out in triplicate and the mean of the successive readings was used to 
calculate the acid-value of the respective sample by following expression. 
Acid value = Titter Value X 0.00561X 1000 / Wt of test sample (g) 
 
Peroxide value 
5 g of the substance being examined, accurately weighed, into a 250-ml glass-
stoppered conical flask, add 30 ml of a mixture of 3 volumes of glacial acetic acid and 2 
volumes of chloroform, swirl until dissolved and add 0.5ml volumes of saturated 
potassium iodide solution. Allow to stand for exactly 1 minute, with occasional shaking, 
add 30 ml of water and titrate gradually, with continuous and vigorous shaking, with 
0.01M sodium thiosulphate until the yellow colour almost disappears. Add 0.5 ml of 
starch solution and continue the titration, shaking vigorously until the blue colour just 
disappears (a ml). Repeat the operation omitting the substance being examined (b ml). 
The volume of 0.01M sodium thiosulphate in the blank determination must not exceed 
0.1 ml.  
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B. BIOCHEMICAL ANALYSIS OF SILVISHA USIDHAM: 
 
The chemical analysis of Silvisha Usidham was carried out in Bio chemistry lab, 
National Institute of Siddha. 
 
S.No EXPERIMENT OBSERVATION 
1.  Physical Appearance of extract Pale yellowish in colour 
2. Test for Silicate 
     A 500mg of the sample was shaken 
well with distilled water. 
Sparingly soluble 
3. Action of Heat: 
   A 500mg of the sample was taken in 
a dry test tube and heated gently at 
first and then strong. 
 
No White fumes 
evolved. 
4. Flame Test: 
  A 500mg of the sample was made 
into a paste with Con. HCl in a watch 
glass and introduced into non-
luminous part of the Bunsen flame. 
 
No bluish green flame 
 
5. Ash Test: 
A filter paper was soaked into a 
mixture of extract and dil. cobalt 
nitrate solution and introduced into the 
Bunsen flame and ignited. 
 
 
No  yellow color flame 
 
 
 
 
 
flame 
 
 
 
flame 
 
Preparation of Extract: 
5gm of sample was taken in a 250ml clean beaker and added with 50ml of 
distilled water. Then it was boiled well for about 10 minutes. Then it was cooled and 
filtered in a 100ml volumetric flask and made up to 100ml with distilled water. This 
preparation was used for the qualitative analysis of acidic/basic radicals and biochemical 
constituents in it. 
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S.No EXPERIMENT OBSERVATION 
 I. Test For Acid Radicals  
1. Test For Sulphate: 
2ml of the above prepared extract was taken in 
a test tube to this added 2ml of 4% dil 
ammonium  oxalate solution 
Cloudy appearance  
present 
2. Test For Chloride: 
2ml of the above prepared extract was added 
with 2ml of dil-HCl until the effervescence 
ceases off. 
No Cloudy 
appearance was 
formed 
3. Test For Phosphate: 
2ml of the extract was  treated with 2ml of 
dil.ammonium molybdate solution and 2ml of 
Con.HNo3 
No  Cloudy yellow 
appearance present 
4. Test For Carbonate: 
2ml of the extract was treated with 2ml dil. 
magnesium sulphate solution. 
Cloudy appearance 
present. 
5. Test For Nitrate: 
1gm of the extract was heated with copper 
turning and concentrated H2So4 and viewed 
the test tube vertically down. 
No Brown gas was 
evolved 
6. Test For Sulphide: 
1gm of the extract was treated with 2ml of 
Con. HCL 
No rotten egg 
smelling gas was 
evolved 
7. Test For Fluoride & Oxalate: 
2ml of extract was added with 2ml of dil. 
Acetic acid and 2ml dil. calcium chloride 
solution and heated. 
No cloudy 
appearance. 
 
8. 
 
Test For Nitrite: 
3drops of the extract was placed on a filter 
paper, on that-2 drops of dil.acetic acid and 2 
drops of dil.Benzidine solution were placed. 
No characteristic 
changes were 
noted. 
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9. 
 
 
 
Test For Borate: 
2 Pinches (50mg) of the extract was made into 
paste by using dil.sulphuric acid and alcohol 
(95%) and introduced into the blue flame. 
No Appearance of 
bluish green color. 
II. Test For Basic Radicals 
1. Test For Lead: 
2ml of the extract was added with 2ml of 
dil.potassium iodine solution. 
No Yellow 
precipitate was 
obtained 
2. Test For Copper: 
One pinch (25mg) of extract was made into 
paste with Con. HCl in a watch glass and 
introduced into the non-luminuous part of the 
flame. 
 
No blue colour 
appeared 
 
3. Test For Aluminium: 
To the 2ml of extract dil.sodium hydroxide 
was added in 5 drops to excess. 
No yellow Colour  
appeared 
 
 
 
 
 
 
 
 
 
characteristic 
changes chara 
4. Test For Iron: 
a. To the 2ml of extract, added 2ml of 
dil.ammonium solution 
b. To the 2ml of extract 2ml  thiocyanate 
solution and 2ml  of con HNO3 were added 
Mild Red colour 
appeared 
 
 
5. Test For Zinc: 
To 2ml of the extract dil. sodium hydroxide 
solution was added in 5 drops to excess and 
dil. ammonium chloride was added. 
No White 
precipitate was  
formed 
 
6. 
Test For Calcium: 
2ml of the extract was added with 2ml of 4% 
dil.ammonium oxalate solution 
No Cloudy 
appearance and 
white precipitate 
was formed 
 
7. Test For Magnesium: 
To 2ml of extract dil. sodium hydroxide 
solution was added in 5 drops to excess. 
No  White 
precipitate was 
obtained 
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8. Test For Ammonium: 
To 2ml of extract 1 ml of Nessler's reagent and 
excess of dil.sodium hydroxide solution were 
added. 
Brown colour 
appeared 
9. Test For Potassium: 
A pinch (25mg) of extract was treated with 
2ml of dil. sodium nitrite solution and then 
treated with 2ml of dil. cobalt nitrate in 30% 
dil. glacial acetic acid. 
No Yellow 
precipitate was 
obtained 
10. Test For Sodium: 
2 pinches (50mg) of the extract was made into 
paste by using HCl and introduced into the 
blue flame of Bunsen burner. 
No yellow colour 
flame evolved. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
of yellow colour 
11. Test For Mercury: 
2ml of the extract was treated with 2ml of dil. 
sodium hydroxide solution. 
No Yellow 
precipitate was 
obtained 
12. Test For Arsenic: 
2ml of the extract was treated with 2ml of dil. 
sodium hydroxide solution. 
No  Brownish red 
precipitate was 
obtained 
 
III. Miscellaneous 
1. 
Test For Starch: 
2ml of extract was treated with weak dil.Iodine 
solution 
Blue colour   
developed 
2. 
Test For Reducing Sugar: 
5ml of Benedict's qualitative solution was taken in a 
test tube and allowed to boil for 2 minutes and added 8 
to 10 drops of the extract and again boil it for 2 
minutes. The colour changes were noted. 
No Brick red 
colour is 
developed 
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3. 
Test For The Alkaloids: 
a) 2ml of the extract was treated with 2ml of 
dil.potassium lodide solution. 
b)  2ml of the extract was treated with 2ml of dil.picric 
acid. 
c)  2ml of the extract was treated with 2ml of 
dil.phosphotungstic acid. 
 
 
Yellow 
colour 
developed 
4 
Test For Tannic Acid: 
2ml of extract was treated with 2ml of dil. ferric 
chloride solution 
  
No Blue-
black 
precipitate 
was obtained 
5 
Test For Unsaturated Compound: 
To the 2ml of extract, 2ml of dil. Potassium 
permanganate solution was added. 
Potassium 
permanganate 
was not 
decolourised 
6 
Test For Amino Acid: 
2 drops of the extract was placed on a filter paper and 
dried well. 20ml of Burette reagent was added. 
No Violet 
colour 
appeared 
 
7 
Test For Type of Compound: 
2ml of the extract was treated with 2 ml of dil. ferric 
chloride solution. 
No green and 
red colour 
developed 
 
No Violet 
colour 
developed 
 
No Blue 
colour 
developed. 
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C. ACUTE  TOXICITY  STUDY : 
 
TOXICOLOGICAL EVALUATION OF SILVISHA USIDHAM (SU) 
            
The following in vivo toxicity studies were carried out on Silvisha Usidham (SU) 
by World Health Organization (WHO) guideline 
39
.  Acute Oral Toxicity study (WHO)   
        
The toxicity studies were carried out at National Institute of Siddha. The study 
was done after getting permission from the Institutional Animal Ethics Committee.   
IAEC Approved No:  For acute toxicity study – NIS/IAEC-IV/05/05012017  
 
For Acute toxicity studies test animals were obtained from Tamil Nadu 
Veterinary and Animal Sciences University, Madhavaram. Animals were kept in animal 
house at National Institute of Siddha, Chennai.  
 
DESCRIPTION OF THE METHOD  
Selection of the animals:  
             Animals were selected as per guidelines. Healthy adult animals of Wistar albino 
rat, both male and female sex were used for acute oral toxicity study. The female animals 
used in the studies were nulliparous and non-pregnant.  
 
Housing and feeding conditions:  
 The temperature in the experimental animal room: 22ºC (± 3ºC) 
 Humidity: 60 ± 10 %  
 Lighting   : Artificial, the sequence being 12 hours light, 12 hours dark. 
         The animals were housed in polypropylene cages provided with bedding of husk. 
The animals had free access to RO water. For feeding, Standard pellet diet (bought from 
SaiMeera foods pvt. Ltd, Bangalore) was used.  
 
Preparation of animals:                      
              The animals were randomly selected, to permit individual identification by cage 
number and individual marking on the fur of each animals was made with picric acid. 
The animals were kept in their cages for 7 days prior to dosing to allow for 
acclimatization to the laboratory conditions. The principles of laboratory animal care 
were followed.  
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Test Substance:         
         Silvisha Usidham (SU) is pale yellowish in colour, free flowing- greasy and 
Slightly pungent. 
 
Route of administration:     
          Oral route was selected, because it is the normal route of clinical administration.  
  
PROCEDURE:  
ACUTE ORAL TOXICITY STUDY  
Experimental Animals: 
Species and strain                      : Wistar Albino rat 
 Sex                                            : Male and Female  
Age, Weight                               : 6-8 weeks, 150-175 gm 
 Test guideline                            : WHO guideline   
Groups/treatment                        : Grouped by randomization  
Duration of exposure to the        : Silvisha Usidham (SU) Single dose  
Study duration                            : 14 days 
 Number of animals                    : 10 male, 10 female 
 Route of administration             : Oral 
 
Number of animals and dose levels:  
Animals are divided into two groups, each group containing 5 male and 5 female 
rats. One group as control and the other as test group. Control group is treated with saline 
and other groups were treated with test drug Silvisha Usidham (SU) ten times the 
therapeutic dose (5000mg per kg b.wt).  
 
Groups No. of Rats 
Group I  Vehicle control (saline ) 5 male, 5 female 
Group II  Test drug –Silvisha Usidham (SU)   (5000mg per 
kg b.wt) 
5 male, 5 female 
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Administration of doses:  
            The test drug was administered in a single dose by using oral gavage. Animals 
were fasted prior to drug administration. Following the period of fasting, the animals 
were weighed and test drug was administered. The control groups received equal volume 
saline. The test drug was administered at 10 times the therapeutic dose (5000 mg per kg 
b.wt). The food was withheld for 3-4 hours after dosing the animal.  
 
Observations:  
        Observations were made and recorded systematically and continuously observed 
after the substance administration as per the guidelines.  
 ½ hour, 1 hour, 2 hours, 4 hours and up to 24 hours observation 
 All rats were observed twice daily for 14 days  
 Body weight  were Calculated weekly once   
 Feed & water intake  were Calculated daily 
 
Cage side observation   
The animals were monitored for behavioral parameters like Alertness, 
Aggressiveness, piloerection, Grooming, Gripping, Touch Response, Motor Activity, 
Tremors, Convulsions, Muscle Spasm, Catatonia, Muscle relaxant, Hypnosis Analgesia, 
Lacrimation, Exophthalmos, Diarrohea, Writhing,  Respiration and  Mortality  
Gross necropsy:  
At the end of the 14th day, all the animals were sacrificed by using the injection 
of Pentothal sodium Gross necropsy includes examinations of the external surface of the 
body, all orifices, cranial, thoracic and abdominal cavities and their contents. Brain, eye, 
lungs, heart, spleen, liver, kidneys, adrenal and sexorgans of all animals. 
 
D. PHYTOCHEMICAL ANALYSIS 
Test for alkaloids: 
Mayer's Test: To the test sample, 2ml of mayer's reagent was added, a dull white 
precipitate revealed the presence of alkaloids. 
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Test for coumarins:  
To the test sample, 1 ml of 10% sodium hydroxide was added. The presence of 
coumarins is indicated by the formation of yellow color. 
Test for saponins:  
To the test sample, 5 ml of water was added and the tube was shaken vigorously. 
Copious lather formation indicates the presence of Saponins. 
Test for tannins:  
To the test sample, ferric chloride was added, formation of a dark blue or 
greenish black color showed the presence of tannins. 
 
Test for glycosides- Borntrager’s Test 
Test drug is hydrolysed with concentrated hydrochloric acid for 2 hours on a 
water bath, filtered and the hydrolysate is subjected to the following tests. To 2 ml of 
filtered hydrolysate, 3 ml of choloroform is added and shaken, choloroform layer is 
separated and 10% ammomia solution is added to it. Pink colour indicates presence of 
glycosides. 
Test for flavonoids: 
To the test sample about 5 ml of dilute ammonia solution were been added 
followed by addition of few drops of conc. Sulfuric acid. Appearance of yellow color 
indicates the presence of Flavonoids. 
Test for phenols: 
Lead acetate test: To the test sample; 3 ml of 10% lead acetate solution was 
added.  A bulky white precipitate indicated the presence of phenolic compounds. 
Test for steroids: 
To the test sample, 2ml of chloroform was added with few drops of conc. 
Sulphuric acid (3ml), and shaken well. The upper layer in the test tube was turns into red 
and sulphuric acid layer showed yellow with green fluorescence. It showed the presence 
of steroids. 
Triterpenoids 
Liebermann–Burchard test: To the chloroform solution, few drops of acetic 
anhydride was added then mixed well. 1 ml concentrated sulphuric acid was added from 
the sides of the test tube, appearance of red ring indicates the presence of triterpenoids. 
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Test for Cyanins 
A. Aanthocyanin: 
To the test sample, 1 ml of 2N sodium hydroxide was added and heated for 5 min at 
100
o
C. Formation of bluish green colour indicates the presence of anthocyanin. 
Test for Carbohydrates - Benedict’s test 
To the test sample about 0.5 ml of Benedic‟s reagent is added. The mixture is 
heated on a boiling water bath for 2 minutes. A characteristic coloured precipitate 
indicates the presence of sugar. 
Proteins (Biuret Test) 
To extracts 1% solution of copper sulphate was added followed by 5% solution of 
sodium hydroxide, formation of violet purple colour indicates the presence of proteins.
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Fluorescence analysis in dried powder  
Sample SUwas subjected to fluorescence analysis under visible light and UV – 
Light at 365 nm under closed circuit cabinet. Each fluorescence characteristic of the 
treated sample was observed under ordinary light and then under UV light of wave 
lengths 365 nm. The drug was treated with acids viz., Conc. HCl, Conc. H2SO4, Conc. 
HNO3 and glacial acetic acid. The drug was treated with alkaline solutions viz., aqueous 
NaOHand ferric chloride. They were subjected to fluorescence analysis in visible light 
and in short UV- light (254 nm) and long UV- light (365 nm). 
 
Reference 
Evans WC. In: Trease and Evans‟ Pharmacognosy. Harcourt Baraco and Company 
Asia Pvt. Ltd. Singapore; 1996: 1–437. 
 
E. QUANTITATIVE ANALYSIS: 
 
HEAVY METAL ANALYSIS BY AAS 
Standard: Hg, As, Pb and Cd – Sigma 
 
Methodology 
Atomic Absorption Spectrometry (AAS) is a very common and reliable technique 
for detecting metals and metalloids in environmental samples. The total heavy metal 
content of the sample SU was performed by Atomic Absorption Spectrometry (AAS) 
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Model AA 240 Series. In order to determination the heavy metals such as mercury, 
arsenic, lead and cadmium concentrations in the test sample SU 
 
Sample Digestion 
Test sample SU digested with 1mol/L HCl for determination of arsenic and 
mercury. Similarly for the determination of lead and cadmium the sample were digested 
with 1mol/L of HNO3. 
 
Standard reparation 
As & Hg- 100 ppm sample in 1mol/L HCl 
Cd & Pb- 100 ppm sample in 1mol/L HNO3 
 
TLC Analysis 
Test sample was subjected to thin layer chromatography (TLC) as per 
conventional one dimensional ascending method using silica gel 60F254, 7X6 cm 
(Merck) were cut with ordinary household scissors. Plate markings were made with soft 
pencil. Micro pipette were used to spot the sample for TLC applied sample volume 10-
micro liter by using pipette at distance of 1 cm at 5 tracks. In the twin trough chamber 
with different solvent system Toulene: Ethyl Acetate: Acetic Acid (1.5:1:0.5) After the 
run plates are dried and was observed using visible light Short-wave UV light 254nm 
and light long-wave UV light 365 nm 
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High Performance Thin Layer Chromatography Analysis 
HPTLC method is a modern sophisticated and automated separation technique 
derived from TLC. Pre-coated HPTLC graded plates and auto sampler was used to 
achieve precision, sensitive, significant separation both qualitatively and quantitatively. 
High performance thin layer chromatography (HPTLC) is a valuable quality assessment 
tool for the evaluation of botanical materials efficiently and cost effectively. HPTLC 
method offers high degree of selectivity, sensitivity and rapidity combined with single-
step sample preparation. In addition it is a reliable method for the quantitation of nano 
grams level of samples. Thus this method can be conveniently adopted for routine 
quality control analysis. It provides chromatographic fingerprint of phytochemicals 
which is suitable for confirming the identity and purity of medicinal plant raw materials.  
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Chromatogram Development 
It was carried out in CAMAG Twin Trough chambers. Sample elution was 
carried out according to the adsorption capability of the component to be analysed. After 
elution, plates were taken out of the chamber and dried. 
 
Scanning 
Plates were scanned under UV at 366nm. The data obtained from scanning were 
brought into integration through CAMAG software. Chromatographic finger print was 
developed for the detection of phytoconstituents present in each extract and Rf values 
were tabulated.
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Test for Specific Pathogen 
Methodology 
About 0.5 gms of test sample was directly inoculated in to the specific pathogen 
medium (EMB, DCC, Mannitol, Cetrimide) by spread plate method. The plates were 
incubated at 37
o
C for 24 - 72h for observation. Presence of specific pathogen identified 
by their characteristic color with respect to pattern of colony formation in each 
differential media. 
 
Abbreviation 
 
Organism Abbreviation 
E-coli EC 
Salmonella SA 
Staphylococcus Aureus ST 
Pseudomonas Aeruginosa PS 
 
Observation 
No growth was observed after incubation period. Reveals the absence of specific 
pathogen 
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STERILITY TEST BY POUR PLATE METHOD 
 
Objective  
The pour plate techniques were adopted to determine the sterility of the product. 
Contaminated / un sterile sample (formulation) when come in contact with the nutrition 
rich medium it promotes the growth of the organism and after stipulated period of 
incubation the growth of the organism was identified by characteristic pattern of 
colonies. The colonies are referred to as Colony Forming Units (CFUs).   
 
Methodology 
About 1ml of the test sample was inoculated in sterile petri dish to which about 
15 mL of molten agar 45
o
C were added. Agar and sample were mixed thoroughly by 
tilting and swirling the dish. Agar was allowed to completely gel without disturbing it. 
(about 10 minutes). Plates were then inverted and incubated at 37
o
 C for 24-48 hours. 
Grown colonies of organism was then counted and calculated for CFU. 
 
Observation 
No growth was observed after incubation period. Reveals the absence of specific 
pathogen 
 
PESTICIDE RESIDUE: 
 
Extraction 
About 10 g weight equivalent to test substance were extracted with 100 ml of 
acetone and followed by homogenization for brief period. Further filtration was allowed 
and subsequent addition of acetone to the test mixture. Heating of test sample was 
performed using a rotary evaporator at a temperature not exceeding 40ºC until the 
solvent has almost completely evaporated. To the residue add a few milliliters of toluene 
R and heat again until the acetone is completely removed. Resultant residue will be 
dissolved using toluene and filtered through membrane filter 
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AFALOTOXIN: 
Standard 
Aflatoxin B1 
Aflatoxin B2 
Aflatoxin G1 
Aflatoxin G2 
 
Solvent 
Standard samples was dissolved in a mixture of chloroform and acetonitrile (9.8 : 
0.2) to obtain a solution having concentrations of 0.5 μg per ml each of aflatoxin B1 and 
aflatoxin G1 and 0.1 μg per ml each of aflatoxin B2 and aflatoxin G2. 
 
Test solution: Concentration 1 μg per ml 
Procedure 
Standard aflatoxin was applied on to the surface to pre coated TLC plate in the 
volume of 2.5 μL, 5 μL, 7.5 μL and 10 μL. Similarly the test sample was placed and 
Allow the spots to dry and develop the chromatogram in an saturated chamber containing 
a solvent system consisting of a mixture of chloroform, acetone and isopropyl alcohol 
(85 : 10 : 5) until the solvent front has moved not less than 15 cm from the origin. 
Remove the plate from the developing chamber, mark the solvent from and allow the 
plate to air-dry. Locate the spots on the plate by examination under UV light at 365 nm. 
 
The Physiochemical, phytochemical analysis, heavy metal analysis, Specific 
pathogen test, pesticide residue, aflatoxin, TLC  of the drug Silvisha Usidham was done 
at Noble Research Solution. 
 
F. PHARMACOLOGICAL ACTIVITY 
 
In-vitro Anti-Inflammatory Activity by Protein (Albumin) denaturation Assay 
 
Albumin Denaturation Assay Procedure 
In-vitro anti-inflammatory activity SUwas studied using albumin denaturation 
technique. The reaction mixture consisted of bovine serum albumin (5% aqueous 
solution) and test sample SU at varying concentration ranges from 100 to 500 µg/ml and 
standard Diclofenac sodium at the concentration of100 µg /ml of final volume.  
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pH was adjusted by using a small amount of 1N Hydrochloric acid. The samples 
were incubated at 37°C for 20 min and then heated at 57°C for 3 min. After cooling the 
sample, 2.5 ml of phosphate buffer solution was added into each test tube. Turbidity 
developed was measured spectrophotometrically at 660 nm, for control distilled water 
was used instead of test sample while product control tests lacked bovine serum albumin. 
The experiment was performed in triplicate. The Percentage protection from denaturation 
is calculated by using the formulae 
 
 
 
Statistical analysis 
Results are expressed as Mean ± SD. The difference between experimental 
groups was compared by One-Way Analysis Of Variance (ANOVA) followed by Dunnet 
Multiple comparison test.
37, 38 . 
The anti-inflammatory activity of the drug Silvisha Usidham was done at Noble 
Research Solution. 
 
CLINICAL STUDIES 
All the 30 cases were selected from the OPD of Kuzhandhai Maruthuvam 
Department, National Institute of Siddha. They were treated with the trial drug Silvisha 
Usidham (Internal) and Puzhuvettu Thylam (External) and observed for clinical 
prognosis. 
 
STUDY DESIGN AND CONDUCT OF STUDY: 
   Study type  :  An open clinical study 
   Study place:  OPD of Ayothidoss Pandithar Hospital 
                          National Institute of Siddha 
                          Tambaram sanatorium 
                          Chennai - 47. 
  Study duration     : 24Months 
  Treatment Period: 45 Days 
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Population and Sample: 
Population consists of 30 paediatric patients attending the OPD of Ayothidoss 
pandithar Hospital, National Institute of Siddha, Chennai-47. 
The sample consists of patients between 6-12 years of age group fulfilling all the 
inclusion criteria and exclusion criteria. 
 
INCLUSION CRITERIA 
 Patient who complained with symptoms of alopecia areata 
 Hair loss in patches 
 Non scarring 
 Scattered long hairs within the bald area 
 The area of hair loss may tingle or painful 
 Age between 6 -12 years of both sex. 
 Parents/guardian of the patient willing to sign the informed consent. 
 
EXCLUSION CRITERIA: 
 Scarring alopecia 
 Alopecia Universalis 
 Alopecia totalis 
 Vitiligo 
 Atopic dermatitis 
 Thyroid disease 
 Down syndrome 
 Sample size: 30 patients 
 
TREATMENT MEDICINE: 
Silvisha Usidham (Internal) 
 
Dosages: 
 6 -7years   -2ml 
 8-10years -3ml 
 11-12years -4ml 
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Duration :  45days 
Drug Storage :    Prepared medicine were stored in porcelain vessel. 
Dispensing   :  Prepared medicine were given as oil in separate tight container of  
        individual dose. 
 
Siddha method of assessment:  
 Nilam, Kalam, Uyirthathukkal, Udal thathukkal, Envagai thervugal. 
 
OUTCOME: 
SALT   SCORE –Severity of Alopecia Tool Score 
1. Vertex -40% (0.4) of the scalp surface area 
2. Right profile of the scalp-18% (0.18) 
3. Left profile of the scalp-18% (0.8) 
4. Posterior aspect of scalp-24% (0.24) 
SALT Score= Sum of percentage of hair loss in all above mentioned area.
40
 
 
STUDY ENROLLMENT: 
 Patient reporting at the OPD with the clinical symptoms of  Hair loss in patches, 
Scattered long hairs within  the bald area ,non scarring ,area of hair loss may 
tingle or painful sensation were examined clinically for enrolling in this study 
based on the inclusion and exclusion criteria. 
 The patients who are to be enrolled will be informed about the study, trial drug, 
possible outcomes and the objectives of the study in the language and terms 
understandable to them. 
 After ascertaining the patients‟ willingness, informed consent (Form II) were 
obtained in writing from their parents in the consent form. 
 All these patients were given unique registration card in which patients‟ 
Registration number of the study, Address, Phone number and Doctors phone 
number etc. were given, so as to report easily should any complications arise. 
 Complete clinical history, complaints and duration, examination findings-- all 
would be recorded in the prescribed Case sheet proforma and clinical assessment 
forms separately. Screening Form- I will be filled up. Form III,   Form –IV and 
Form –V will be used for recording the patient‟s history, clinical   examination of 
symptoms and signs and laboratory investigations respectively. 
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 Patient will be advised to take the trial drug and appropriate dietary advice will 
be given according to the patients‟ perfect understanding. 
 
 CONDUCT OF THE STUDY : 
 
The trial drug Silvisha Usidham (Internal) and Puzhuvettu Thylam (External) is 
given for 45days.Patients should visit the hospital after 7days once.  At each clinical visit 
clinical assessment is done and prognosis is noted. After the end of the treatment, the 
patient is advised to visit the OPD for another 1 month for follow-up. If any trial patient 
fails to collect the trial drug on the prescribed day will not be allowed to continue and 
will be withdrawn from the study with fresh case being inducted.   
 
DATA MANAGEMENT : 
  
 After enrolling the patient in the study, a separate file for each patient will be 
opened and all forms will be filed in the file. Study No. and Patient No. will be 
entered on the top of  the file for easy identification. Whenever study patient 
visits OPD during the study period, the respective patient file will be taken and 
necessary recordings will be made at the assessment form or other suitable form. 
 The screening forms will be filed separately.The Data recordings in all forms will 
be monitored and scrutinized by Professor and Head of the department of  
Kuzhanthai Maruthuvam . 
 Data analysis were done with the help of Senior research officer (statistics) of 
NIS 
 
ADVERSE EFFECT /   SERIOUS EFFECT MANAGEMENT: 
If the trial patient develops any adverse reaction, he/she would be immediately 
withdrawn from the trial and proper management will be given in OPD of National 
Institute of Siddha. The details of adverse reactions will be recorded in prescribed 
Pharmacovigilance form and the same will be reported to Regional Pharmacovigilance 
centre. 
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ETHICAL ISSUES 
1. To prevent any infection, proper sterilization of lab equipments were used.  
2. No other external or internal medicines were used. There will be no infringement   
    on the rights of patient.    
3. The data collected from the patient will be recorded. The patient will be informed  
    about the diagnosis, treatment and follow-up.  
4. After the consent of the patient (through consent form) they were enrolled in the    
    study.  
5.Informed consent were obtained from the patient explaining in the  
   understandable language to the patient. 
6. Treatment were provided free of cost.  
   7. In conditions of treatment failure, adverse reactions, patients were given 
alternative treatment at the National Institute of Siddha with full care throughout the 
end.  
 
The following ASSESSMENT FORMS were used for data collection: 
 
FORM I                      SCREENING & SELECTION PROFORMA 
FORM II                     CONSENT FORM 
FORM III                    CASE RECORD FORM 
FORM IV                    CLINICAL ASSESSMENT FORM 
FORM V                      DRUG COMPLAINCE 
FORM VI                     PATIENT‟S INFORMATION SHEET 
FORM VII                    WITHDRAWAL FORM 
FORM VIII                    PHARMOCOLOVIGILANCE FORM 
FORM IX                      DIETARY ADVICE FORM 
FORM X                       ASSENT FORM 
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5. RESULTS AND OBSERVATIONS 
QUALITATIVE ANALYSIS 
A.PHYSICO-CHEMICAL ANALYSIS  
Sample Description 
 
 
 
 
Table-1:  State, appearance, Nature and odor of Silvisha Usidham 
State Liquid 
Appearance Pale Yellowish 
Nature Free flowing – Greasy  
Odor Slightly Pungent 
 
From table 1, the Organoleptic characters shows that  Silvisha Usidham is pale 
yellowish in colour,slightly pungent odor,liquid state and the nature is free flowing-
greasy. 
            Table -2: Physico-chemical properties of Silvisha Usidham 
Analytical Report 
 
S.NO Parameter Silvisha Usidham 
1 Specific Gravity 0.9760 
2 Viscosity at 50
o
C (Pa s) 6.905 
3 Refractive index 1.24 
5 Iodoine value (mg I2/g) 104.77 
68 
 
6 
Saponification Value (mg of KOH to 
saponify 1gm of fat) 
149.55 
7 Ph 4 
8 Weight per ml 0.029 g/ml 
9 Acid Value mg KOH/g 0.766 
10 Peroxidase Value mEq/kg 0.528 
 
From table 2, The physicochemical analysis of Silvisha Usidham Explained in the 
parameters such as viscosity, refractive index, Iodine value, Saponification value, 
Peroxidase value are within limit, 
B. BIOCHEMICAL ANALYSIS 
 
Table-3: Test for Acidic radicals on Silvisha Usidham 
 
S.NO Parameter Observation Result 
1 Test for Sulphate 
Cloudy appearance 
present. 
Positive 
2 Test for Chloride - Negative 
3 Test For Phosphate          - Negative 
4 Test For Carbonate 
Cloudy appearance 
present 
Positive 
5 Test For Nitrate - Negative 
6 Test for Sulphide - Negative 
7 Test For Fluoride &oxalate - Negative 
8 Test For Nitrite - Negative 
9 Test For Borax - Negative 
 
(+ve/-ve present or absent if component tested) 
Interpretation 
 The acidic radicals test shows the presence of Sulphate, Carbonate. 
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Table-4: Test for Basic radicals on Silvisha Usidham 
S.NO Parameter Observation Result 
1 Test for Lead - Negative 
2 Test for Copper - Negative 
3 Test For Aluminium. - Negative 
4 Test For Iron. Red colour appeared Positive 
5 Test For Zinc - Negative 
6 Test for Calcium - Negative 
7 Test For Magnesium - Negative 
8 Test For Ammonium Brown colour appeared Positive 
9 Test For Potassium - Negative 
10 Test For Sodium - Negative 
11 Test For Mercury - Negative 
12 Test For Arsenic - Negative 
 
(+ve/-ve present or absent if component tested) 
Interpretation 
 The basic radical test shows the presence of Iron and Ammonium. Absence of 
heavy metals such as lead, arsenic and mercury. 
 
Table-5 : Test for Miscellaneous on Silvisha Usidham: 
 
S.NO Parameter Observation Result 
1 Test for Starch Blue colour developed Positive 
2 Test for Reducing sugars - Negative 
3 Test For Alkaloids. Yellow colour developed Positive 
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4 Test For Tannic acid. - Negative 
5 Test for unsaturated compounds - Negative 
6 Test for Amino acid - Negative 
7 Test For Type of compounds - Negative 
 
(+ve/-ve present or absent if component tested) 
Interpretation: 
The Miscellaneous test shows the presence of Starch and Alkaloid. 
 
c. PHYTOCHEMICAL ANALYSIS REPORT: 
     Table-6 : Test fos Phytochemical Screening on Silvisha Usidham 
 
S.NO TEST OBSERVATION 
1. ALKALOIDS + 
2. FLAVANOIDS - 
3. GLYCOSIDES - 
4. STEROIDS + 
5. TRITERPENOIDS + 
6. COUMARIN + 
7. PHENOL - 
8. TANIN + 
9. PROTEIN - 
10. SAPONINS - 
11. SUGAR - 
12. ANTHOCYANIN - 
13. BETACYANIN - 
 
    Note: +-> Indicates Presence and - -> Indicates Absence of the Phytocomponents. 
71 
 
Interpretation:  
 Phytochemical screening shows presence of Alkaloid, Steroid, Tritrepenoids, 
Coumarin and Tanin. 
 
 Test for Alkaloids                     Test for Flavonoids                      Test for Glycosides 
                                                                
 
 
                                               
 
  Test for Steroids                  Test for Triterpenoids                       Test for Coumarins 
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Test for Phenols             Test for Tanins                        Test for Proteins 
  
 
 
 
                                                                                   
 
 
 
 
 
 
 
Test for Saponins        Test for Carbohydrates           Test for Anto/ Beta cyanins 
 
 
 
                                                              
 
 
 
 
 
 
 
 
 
 
 
73 
 
D. Fluorescence analysis in dried powder 
 
 
Visible light 
 
 
 
Short UV- light (254 nm) 
 
 
74 
 
 
Long UV- light (365 nm) 
 
 
 
Table-7: Fluorescence analysis in dried powder  
 
S.No Experiment Visible light 
Short 
UV – Light 
254 nm 
Long 
UV – Light 
365 nm 
1.  
Sample + Conc. Hcl Mild yellowish Mild yellow 
Florescent 
Yellowish  
2.  
Sample + Conc. Sulphuric 
Acid 
Greenish brown Greenish brown Crimson red 
3.  
Sample + Conc. Nitric acid Lime Yellow Mild Florescent 
yellow 
Crimson brown 
4.  
Sample + Sodium hydroxide 
in water 
Creamy white Pale yellowish white Pale yellow 
5.  Sample + Ferric chloride Reddish orange Florescent green Reddish brown 
6.  Sample + glacial acetic acid Turbid white Milky white Pale Yellow 
7.  Sample + Water  White Milky white Pale yellow 
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E. HEAVY METAL ANALYSIS 
 
Table-8: Heavy metal analysis on Silvisha Usidham 
 
Name of the heavy 
metal 
Absorption max 
A max 
Result 
analysis 
Maximum limit 
Mercury 253.7nm BDL 1ppm 
Lead 217.0nm 0.010ppm 10ppm 
Arsenic 193.7nm BDL 3ppm 
Cadmium 228.8nm BDL 0.3ppm 
 
BDL- Below Detection Limit 
 Inference 
 Results of the present investigation has clearly shows that the sample SU has no 
traces of Mercury, Arsenic and Cadmium and hence it was considered that these 
heavy metals was absent in the sample SU. 
 The reported heavy metal lead seems very low (0.010 ppm) when compare to the 
allowed recommended limit of 10 ppm. 
 
      F. Test for Specific Pathogen 
Table-9: Specfic Pathogen test on Silvisha Usidham 
Organism Specification Result Method 
E-coli Absent Absent 
As per AYUSH 
specification 
Salmonella Absent Absent 
Staphylococcus aureus Absent Absent 
Pseudomonas aeruginosa Absent Absent 
 
Result 
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No growth / colonies were observed in any of the plates inoculated with the 
Silvisha Usidham. 
Culture plate with E-coli and Salmonella specific medium 
 
Culture plate with Staphylococcus Aureus specific medium 
     
Culture plate with Pseudomonas Aeruginosa specific medium 
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        G . STERILITY TEST BY POUR PLATE METHOD 
Table-10: Sterilty test by pour plate method 
Test Result Specification As per AYUSH/WHO 
Total Bacterial Count Absent NMT 10
5
CFU/g As per AYUSH 
specification Total Fungal Count Absent NMT 10
3
CFU/g 
 
Result 
No growth / colonies were observed in any of the plates inoculates with the 
Silvisha Usidham. 
 
 
   
 
 
 
 
H. AFLATOXIN REPORT 
Table-11: Aflatoxin test on Silvisha Usidham 
AFLATOXIN SAMPLE SU AYUSH Specification 
B1 Not Detected-Absent 0.5ppm 
B2 Not Detected-Absent 0.1ppm 
G1 Not Detected-Absent 0.5ppm 
G2 Not Detected-Absent 0.1ppm 
 
 Result:  
The results shows that there was no spots were been identified in the Silvisha 
Usidham loaded TCL plate when compare to the standard indicates that the Silvisha 
Usidham  were free from AflatoxinB1, Aflatoxin B2, Aflatoxin G1, Aflatoxin G2. 
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I. Pesticide Residue 
Table-12: Test for pesticide residue on Silvisha Usidham 
 
Pesticide Residue 
I.Organo chlorine Pesticides 
Sample SU AYUSH Limit (mg/kg) 
Alpha  BHC BQL 0.1mg/kg 
Beta  BHC BQL 0.1mg/kg 
Gamma  BHC BQL 0.1mg/kg 
Delta  BHC BQL 0.1mg/kg 
DDT BQL 1mg/kg 
Endosulphan BQL 3mg/kg 
II. organo Phosphorus Pesticides   
Malathion BQL 1mg/kg 
Chlorpyriphos BQL 0.2mg/kg 
Dichlorovos BQL 1mg/kg 
III.Pyrethroid   
Cypermethrin 0.2mg/kg 1mg/kg 
 
BQL-Below quantification  Limit. 
 
Result:  
The results showed that there were no traces of pesticides residue such as organo 
chlorine and organo phosphorus pesticides such as Organo chlorine and Organo 
phosphorus Pesticides in the sample SU. Further Silvisha Usidham shows the presence of 
Cypermethrin belongs to Pyrethroid type of pesticides at the concentration of 0.2 mg/kg 
which was low compare the AYUSH prescribed limit of 1mg/kg 
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J.  HPTLC REPORT: 
Table-13: HPTLC finger printing analysis of the Silvisha Usidham 
 
Peak Start 
Rf 
Start  
Height 
Max 
Rf 
Max 
Height 
Max% End  
Rf 
End 
Height 
Area Area 
% 
1. 0.10 9.7 0.12 22.8 9.10 0.13 20.3 333.6 7.45 
2. 0.36 9.9 0.39 20.2 8.06 0.44 6.4 694.8 15.51 
3. 0.56 5.3 0.61 51.6 20.61 0.62 20.3 1074.4 23.98 
4. 0.63 20.9 0.64 42.6 17.05 0.67 5.3 749.1 16.72 
5. 0.71 1.8 0.75 49.6 19.84 0.76 41.1 743.0 16.58 
6. 0.67 42.6 0.77 51.1 20.44 0.79 16.4 638.8 14.26 
7. 0.84 2.8 0.86 12.3 4.90 0.88 5.4 247.2 5.52 
 
RESULT:    
 HPTLC finger printing analysis of the Silvisha Usidham reveals the presence of 
seven prominent peaks corresponds to presence of seven versatile phytocomponents 
present within it. Rf value of the peaks ranges from 0.10 to 0.84.Further the peak 3 
occupies the major percentage of area of 23.98% which denotes the abundant existence 
of such compound .Followed by this peak 4 and 5 occupies the percentage area of 16.72 
and 16.58%. 
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TLC Analysis at 254 nm                                          TLC Analysis at 366 nm 
                                                         
                                    HPTLC finger printing of Sample SU 
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K. PHARMACOLOGICAL ACTIVITY: 
In-vitro Anti-Inflammatory Activity by Protein (Albumin) denaturation Assay 
FINAL RESULT 
Concentration in µg/ml Absorbance 
Control 0.981  ± 0.008 
SU 100 0.926  ± 0.020 
SU 200 0.86  ± 0.01 
SU 300 0.796  ± 0.0057 
SU 400 0.733  ± 0.015 
SU 500 0.68  ± 0.026 
Diclofenac sodium (100 µg) 0.023  ± 0.024 
 
Each value represents the mean ± SD. N=3 
Concentration in µg/ml 
Percentage Inhibition of 
Protein Denaturation 
SU 100 3.64  ± 1.152 
SU 200 10.44  ± 0.767 
SU 300 16.89  ± 1.06 
SU 400 23.35  ± 1.409 
SU 500 28.79  ± 2.389 
Diclofenac sodium  (100 µg) 95.69  ± 2.349 
 
Each value represents the mean ± SD. N=3 
Result Analysis 
The result obtained from the present clearly indicates that the test drug SU was 
effective in inhibiting heat induced albumin denaturation. Maximum percentage 
inhibition of about 28.79 % was observed at 500 μg/ml when compare to that of the 
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Diclofenac sodium, a standard anti-inflammatory agent with the maximum inhibition 
95.69 % at the concentration of 100 μg/ml. 
 
Conclusion 
From the result of the study it was concluded that the test drug SU possess 
convincing  anti-inflammatory property in protein denaturation assay. 
Preparation of Test and control 
 
Absorbance of reaction mixture – Test Sample 
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Absorbance of reaction mixture – Control and Standard 
 
Absorbance Range of test and standard at Trial 1 
 
Absorbance Range of test and standard at Trial 2 
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Absorbance Range of test and standard at Trial 3 
 
L. ACUTE TOXICITY STUDY 
Table-14: Behavioral Signs of Acute Toxicity Study of Silvisha Usidham 
Parameters 
30 mints 
 
4 hrs 24 hrs 1
st
 week 2
nd
 week 
C T C T C T C T C T 
Skin & Fur N N N N N N N N N N 
Mucous Membrane N N N N N N N N N N 
Respiratory rate N N N N N N N N N N 
Heart rate N N N N N N N N N N 
Salivation & 
Lacrimation 
N N N N N N N N N N 
Lethargy NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL 
Piloerection N N N N N N N N N N 
Urinary incontinence NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL 
Defecation N N N N N N N N N N 
Sleep & Gait N N N N N N N N N N 
Tremors &Convulsion NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL 
Mortality NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL 
 
N – Normal, C – control, T- Test Group 
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All the data were summarized in the form of revealed that there was no abnormal 
signs and behavioural changes in all animals at the dose level of 5,000 mg/kg body 
weight administered orally, during the study period.   
             There was no mortality observed after dosing of Silvisha Usidham upto 
5000mg/kg body weight during the study period of 14 days. This indicates that the LD50 
of Silvisha Usidham is more than 5000mg/kg b.wt.  
            There were no changes in skin and fur, eyes and mucous membranes of all 
animals.  The eating, drinking habit, sleep pattern, locomotion were normal in all animals 
and no changes in body weight as compared to control group.  
           At the end of the 14 the day, necropsy was performed and there was no 
abnormality seen in test groups as compared to control group during the examination. 
 
Clinical studies 
30 Patients with confirmed diagnosis of Puzhuvettu with satisfying the inclusion 
criteria were enrolled after obtaining written informed consent and were to receive 
Silvisha Usidham with dosage of 2-4ml BID and Puzhuvettu Thylam external for 45 
days. 
Results were observed with respect to the following criteria: 
1. Sex distribution 
2. Age distribution 
3. Parent‟s socio economic status 
4. Duration of illness 
5. Diet 
6. Family History 
7. Habit 
8. Nilam 
9. Kaalam distribution 
10. Yakkai 
11. Gunam 
12. Uyirthathukal.  
13. Udarthathukkal 
14. Envagai thervugal 
15. Neikuri 
16. Area affected 
17. SALT Score 
.   
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1. GENDER DISTRIBUTIONS: 
 
Table-15:  Distributions of patient with Puzhuvettu according to Gender 
 
 
SI.NO Sex No of Cases Percentage 
1. Male child 9 30 
2. Female child 21 70 
 
  
 
 
 
Inference: 
     Out of 30 patient 30% were male children and 50% were female children (Table15) 
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Table-16:  Distribution of Patients with Puzhuvettu according to Age 
 
S.NO Age No of Cases Percentage 
1. 6-9 years 18 60 
2. 10-12 years 12 40 
 
 
 
 
 
 
 
 
 
 
Inference:   
            Out of 30 patients, 60% of cases were 6-9 years, 40% were 10-12 years. 
(Table16) 
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Table-17:  Distribution of patients with Puzhuvettu according to Socio-economic 
status 
S.NO Socio-economic status No of cases Percentage 
1. Poor 3 10% 
2. Middle class 18 
60% 
 
3. Rich 9 
30% 
 
 
 
Inference:      
                About 10% Patients were under lower income group, 60% Patients were under 
middle income group and 30% patients were under high income group. The high 
incidences were in middle income group. 
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Table-18:  Distribution of patient with Puzhuvettu according to Duration of Illness 
 
S.NO Duration No of cases Percentage 
1. 1Day-3Months 15 50% 
2. 4Months-6Months 7 23.33% 
3. 7Months-1Year 5 16.66% 
4. 2Year-5Year 3 10% 
 
   
 
Inference: 
    According to duration of the illness, high incidence of case (50%) was noted in 
1day-3months duration, 23.33%  cases noted in 4months-6months duration, 16.66% 
cases noted in 7months-1year duration and 10% cases were noted in 2years-5years 
duration.  
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Table-19:  Distribution of patients with Puzhuvettu according to Diet reference 
 
S.NO FOOD HABIT No of Cases 
Percentage 
 
1. Vegetarian 1 
3.3% 
 
2. Mixed  29 
96.6% 
 
 
 
 
Inference:  
     According to diet, high incidence of cases (96.6%) was noted in mixed diet and in 
Vegetarian c 3.33% cases were noted. 
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Table-20:  Distribution of patients of Puzhuvettu according to Family history 
 
S.NO History No of cases Percentage 
1. Family history 3 10 
2. No Family history 27 90 
 
 
 
Inference: 
    According to Family history 10% case were reported as known family history and 
90% cases were reported as no relevant family history.    
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Table-21:  Distribution of patients of Puzhuvettu according to Habit 
 
S.NO Habit No of patient 
Percentage 
 
1. Pica 1 
3.33 
 
2. Thumb sucking 0 
0 
 
3. Nail biting 2 
6.7 
 
4. Bowel Habit 0 
0 
 
5. Enuresis 3 
10 
 
 
 
Inference: 
    Out of 30 cases, 3.33% cases were reported as Pica, 6.7% cases reported as nail biting 
and 10% cases were reported as Enuresis. 
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Table-22:  Distribution of Patients with Puzhuvettu according to Nilam 
 
S.NO Nilam No of cases Percentage 
1. Kurinji 0 0 
2. Mullai 0 0 
3. Marutham 4 13.33 
4. Neithal 26 86.66 
5. Paalai 0 0 
 
 
 
 
 
 
 
 
 
Inference: 
         Out of 30 cases, 86.7% of cases from Neithal nilam and 13.33% of cases from 
Marutham nilam. (Table 22) 
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Table-23:   Distribution of Patients with Puzhuvettu according to Paruvakalam 
S.NO Paruvakaalam No of cases Percentage 
1. Karkaalam (Avani, Pratasi) 0 
0 
 
2. Koothirkaalam (Iyppasi, Karthigai) 0 
0 
 
3. Munpani (Markazhi, Thai) 10 
33.33 
 
4. Pinpani (Masi- Panguni) 18 
60 
 
5. Elavenil (chitirai, Vaigasi) 2 
6.66 
 
6. 
Mudhuvenil (Aani, Aadi) 
 
0 
0 
 
  
Inference:   
 According to paruvakaalam, high incidence of cases (60%) were reported in 
Pinpanikaalam, 33.33% cases were from Munpanikaalam and 6.66% cases were from 
Elavenil kaalam. (Table 23) 
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Table-24:  Distribution of Patients with Puzhuvettu according to Yakkai 
 
S.NO Yakkai No. of cases Percentage 
1. Vatham 13 43.33 
2. Vathapitham 9 30 
3 Vathakabam 7 23.33 
4. Kabavatham 1 3.33 
 
 
 
Inference: 
               Out of 30 cases, 43.33% cases were reported as vathathegi, 30% cases were 
reported as Vathapitha thegi, 23.33% cases were reported as Vathakaba thegi and 3.33 % 
cases were reported as Kabavatha thegi.(Table24) 
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Table-25:  Distribution of Patients with Puzhuvettu according to Gunam 
S.NO Gunam No of patients 
Percentage 
 
1. Sathuvam 13 
43.33 
 
2. Rasatham 17 
56.7 
 
3. Thamo 0 
0 
 
 
 
Inference:        
                   According to gunam, 43.33% cases were reported as Sathvigam and 56.7% 
cases were reported in Rasatha gunam. (Table 25) 
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Table-26:   Distribution of Patients with Puzhuvettu according to Uyirthathukkal 
VALI   : 
 
S.NO Vatham No of cases Percentage 
1. Pranam 0 
0 
 
2. Abanan 0 
0 
 
3. Viyanan 30 
100 
 
4. Udhanan 0 
0 
 
5. Samanan 30 
100 
 
6. Naagam 0 
0 
 
7. Koorman 0 
0 
 
8. Kirukaran 0 
0 
 
9. Devathathan 0 
0 
 
10. Thananjeyan 0 
0 
 
Inference: 
 According to Vali, derangement of Viyanan and Samanan was 100% affected. 
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Table-27:  Distribution of Patients with Puzhuvettu according to Azhal 
 
S.NO AZHAL No of cases 
Percentage 
 
1. Analapitham 0 
0 
 
2. Ranjagam 0 
0 
 
3. Saathagam 0 
0 
 
4. Prasagam 30 
100 
 
5. Alosagam 0 
0 
 
 
 
Inference: 
             According to Azhal, Derangement of Prasagam was deranged in 100%. 
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Table-28:  Distribution of Patients with Puzhuvettu according to Iyyam 
S.NO Iyyam No of cases Percentage 
1. Avalambagam 3 
10 
 
2. Kilethagam 0 
0 
 
3. Pothagam 0 
0 
 
4. Tharpagam 0 
0 
 
5. Santhigam 0 
0 
 
 
 
Inference: 
     Out of 30 cases derangement of Avalambagam was 10%. 
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Table-29: Distribution of Patients with Puzhuvettu according  derangement of 
Udarthathukal 
S.NO Udarthathukkal No of cases Percentage 
1. Saaram 30 
100 
 
2. Seneer 0 
0 
 
3. Oon 0 
0 
 
4. Kozhuppu 0 
0 
 
5. Enbu 0 
0 
 
6. Moolai 0 
0 
 
7. Sukkilam/Suronitham 0 
0 
 
 
Inference: 
      According to Udarthathukkal Saram was affected in 100% of cases. 
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Table-30: Distribution of Patients with Puzhuvettu according to Envagaithervugal 
 
S.NO Envagaithervugal No of cases 
Percentage 
 
1. Naa 0 
0 
 
2. Niram 0 
0 
 
3. Mozhi 0 
0 
 
4. Vizhi 0 
0 
 
5. Sparisam 30 
100 
 
6. Malam 0 
0 
 
7. Moothiram 0 
0 
 
8. 
Naadi- Vatham 
Vathapitham 
Vathakabam 
Pithavatham 
5 
13 
7 
5 
16.7 
43.33 
23.33 
16.7 
Inference: 
      Out of 30 cases, 100% of cases were affected in Sparisam. 
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Naadi: 
 
Inference:  
 In Naadi, Vatham was observed in16.7% of cases,Vathapitham was observed in 
43.33% of cases, Vathakabam was observed in 23.33%of cases and Pithavatham was 
observed in 16.75% of cases. (Table 16) 
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Table-31:  Distribution of Patients with Puzhuvettu according to observation of 
Neikuri Analysis 
 
S.NO Neikuri reference No of cases 
Percentage 
 
1. Vatham 17 
56.7 
 
2. Pitham 2 
6.6 
 
3. Kabam 8 
26.7 
 
4. Other 3 
10 
 
 
 
Inference:  
                According to Neikuri,Vatha neer was observed in 56.7% of cases, Pitha neer 
was observed in 6.6% of cases, Kaba neer was observed in 26.7% of cases and 10% 
cases was observed in Others. 
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Table-32: Distribution of Patients with Puzhuvettu according to Area affected  
 
S.NO Area affected No of cases Percentage 
1. Single 14 
46.7 
 
2. Multiple 16 
53.33 
 
 
 
 
Inference: 
                  According to area affected out of 30 cases 46.7% was affected by Single area 
and 53.33% was affected by multiple areas. 
 
 
 
105 
 
Table-33:  Distribution of Patients with Puzhuvettu according to SALT Score 
S. NO 
SALT 
Score 
Before treatment After Treatment 
( No of cases) Percentage (No of cases) Percentage 
1. 1-5 9 30% 17 56.7% 
2. 6-10 13 43.33% 9 30% 
3. 11-15 4 13.33% 2 6.7% 
4. 16-20 1 3.33% 1 3.3% 
5. 21-25 1 3.33% 0 - 
6. 26-30 1 3.33% 0 - 
7. 31-35 0 - 1 3.3% 
8. 36-40 1 3.33% 0 - 
          
SALT score-Severity of Alopecia Tool score: Grade I Slightly improvement 
barely noticeable (upto25%), Grade II Moderate improvement noticeable (25-50%), 
Grade III Obvious improvement (51-75%), Grade IV Marked improvement (>75%) 
Table-34:  Grading according to SALT score 
S. No SALT SCORE IMPROVEMENT 
1. 1-5 
Obvious 
 
2. 6-20 
Moderate 
 
3. 21-40 
Slight 
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Inference: 
            Out of 30 cases, 56.7% of cases has obvious improvement, moderate in 40% of 
cases and 3.33% of case were slight improvement. These results were based on the 
Clinical improvements observed by Salt score.   
 
 
STATISTICAL ANALYSIS OF SALT SCORE: 
 
SALT SCORE 
No of Patients 
Mean ± Std Dev Std error 
Significance 
(t value, p value) 
Before (30) 9.4 ± 7.62 1.39 T=7.942,P<  0.0001 
 After   (30) 6.2 ± 6.2 1.13 
 
 
There is considerable significant difference between before and after treatment in 
the SALT score of Puzhuvettu (Alopecia areata).9.4± 7.62 and 6.2± 6.2, P < 0.0001. The 
difference in mean reduction of SALT score was statistically significant. 
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 OP NO: I83043 
AGE/SEX-6/FC 
BEFORE TREATMENT 
 
 
AFTER TREATMENT 
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OP NO: J05415 
AGE/SEX-9/MC 
 
BEFORE TREATMENT 
 
 
AFTER TREATMENT 
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OP NO: K09836 
AGE/SEX-7/FC               
                                             BEFORE TREATMENT 
 
 
AFTER TREATMENT                     
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6. DISCUSSION 
Puzhuvettu is a one of the commonest skin disease in childhood. Puzhuvettu 
resembles alopecia areata in modern literature. The disease is characterized by Patchy 
hair loss in scalp region, itching, non- scarring, well circumscribed loss of hair, atopy 
with exclamation mark hair, associated with nail pitting and ridges. 
In the present study, thirty cases were treated in the outpatient department, 
according to clinical features mentioned in textbook of Sirappu Maruthuvam. The 
Diagnosis is based on clinical observation. The diagnosis were confirmed and treated 
with the drug “Silvisha Usidham” and “Puzhuvettu Thylam” and clearly observed. 
          The Drugs which are mentioned in Siddha literature for the management of 
Puzhuvettu were selected and the study is conducted after the proposal was screened by 
the screening committee of National Institute of Siddha and the trial was also approved 
by the Institutional Ethical Committee (NIS/IEC/2016/11-20/14.10.2016).The trial was 
registered in Clinical trial registry of India (CTRI Reg No :CTRI/2018/01/011311). 
           The trail drugs were prepared by the author in the Gunapadam Practical 
laboratory of National Institute of Siddha, after getting proper authentication of raw 
drugs from the Medicinal botany department at NIS, Chennai-47.The trail drug was 
prepared by the standard operating procedure as mentioned in the protocol. 
 
             The Biochemical analysis of drugs was performed in biochemistry lab of NIS 
and it showed the presence of silicate, sulphate, carbonate, iron, ammonium, starch and 
alkaloid.  
                  In acute toxicity study carried out as per WHO guideline there was no 
yreatment related death of significance of toxicity developed in albino rats at dosage 
level 5000mg/kg/b.wt Throughout the study period no change in behavioural pattern, 
food and water intake,no gross pathological changes have been seen in the internal 
organs of both control and treated groups. Thus the LD50 value was found to be greater 
than 5000mg/kg/b.wt. 
                The Physiocochemical, Phytochemical, heavy metal analysis, Pesticide 
residue, Specific pathogen test, Aflotoxin Assay and Pharmacological activity of the 
drug was done at Noble Research Solution, Chennai.  
             The Phytochemical analysis of Silvisha Usidham constitutes alkaloid, steroids, 
Triterpenoids, coumarin and tanin.  
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 HPTLC finger printing analysis of the Silvisha Usidham reveals the presence of 
seven prominent peaks corresponds to presence of seven versatile phytocomponents 
present within it. Rf value of the peaks ranges from 0.10 to 0.84.Further the peak 3 
occupies the major percentage of area of 23.98% which denotes the abundant existence 
of such compound .Followed by this peak 4 and 5 occupies the percentage area of 16.72 
and 16.58%. 
Heavy metal analysis shows that the heavy metals like Lead, Cadmium, Arsenic 
and Mercury are within the permissible limits.  
           Analysis of microbial load reveals that the drug does not have any microbial 
contamination. 
           The Silvisha Usidham does not show the evidence for the presence of any of the 
aflatoxins  and the Pesticide residue  values are within limit. 
           The Pharmacological studies were done. It revealed that the drug Silvisha 
Usidham possess Anti-inflammatory activities by In-vitro study. 
           The Safety of the trial drug usage through biochemical analysis, heavy metal 
analysis, and toxicity study was also ensured during the study. It revealed the presence of 
effective minerals.  
The patients were recruited for the trial based on inclusion and exclusion criteria 
and after getting the consent from the patient.30 Patients Were included in this study. 
 The 30 patients were treated in OPD of Ayothidoss Pandithar Hospital of 
National Institute of Siddha. Separate proforma was maintained to monitor the clinical 
signs and symptoms of the disease. Progress chart was also maintained to monitor the 
clinical symptoms of the disease. 
           The treatment was aimed at normalizing the deranged thodams and   providing 
relief from symptoms. Before treatment the patients were advised to adapt lifestyle 
modifications such as oil bath weekly twice and to follow good dietary regimen. 
          The patients were treated with trial drugs Silvisha Usidham and Puzhuvettu 
Thylam for 45days.Patients were instructed to take the medicines regularly and advised 
to follow pathiyam and avoid exposure to allergic substance if any. Patients were asked 
to visit the hospital every 7
th
 day for 45 days. 
          After completion of the study, the patients were advised to visit the out-patient 
ward of department of Kuzhanthai Maruthuvam for further follow up. The results 
observed during the study period were discussed by the author below. 
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The study evaluates the effect of “Silvisha Usidham” and “Puzhuvettu Thylam” in 
relieving the symptoms of Puzhuvettu.   
 
CLINICAL REVIEW 
Age: 
        In the present study, out 30 cases 60% were reported between 6-9 years of age 
group and 40% of cases were 10-12 years of age group. 
Sex:   
         Out of 30 cases, 30% (9 cases) were male children and 70% (21 cases) were female 
children. In distribution of sex it was observed that there was high incidence of female 
children than male children. 
Socio-economic status: 
         About 30 cases, 10% (3cases) were under lower income group, 60% (18cases) 
cases were under middle income group and 30% (9cases) were under high income group. 
The highest incidence occurred in middle income group 
Seasonal Variation: 
          Out of 30 cases, 33.33% of cases were reported on Munpani kaalam, 60% of cases 
were reported on Pinpani kaalam and 6.66% of cases were reported on Elavenil kaalam. 
 
Family History: 
             Out of 30 cases, 3 (10%) cases were reported as known family history and 27 
(90%) cases have no relevant family history. 
Food Habit: 
         According to food habits 3.3% of cases had vegetarian diet and 96.6% of cases had 
mixed diet. The highest incidence of cases was observed in Mixed diet of food habits.  
Duration of Illness: 
         According to duration of illness 15 (50%) of cases were reported between 1day-
3months, 7 (23.33%) of cases were reported between 4months-6months, 5 (16.66%) of 
cases were reported between 1year-5years. The highest incidence of cases was observed 
in 1day-3months duration. 
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Nilam:  
          Among 30 cases,4 (13.33%) cases were from Marutham nilam and 26 (86.66%) 
cases were from Neithal nilam. 
Vali (Vatham): 
       Due to the derangement of different vatha the following symptoms occur. Viyanan 
affected in 100% cases and causes and samanan affected in 100% cases. 
Azhal (Pitham): 
          Due to the derangement of Pitham the following symptoms occur Prasagam was 
affected 100% and causes 
Iyyam (Kabam): 
           Deranged Avalambagam was affected 10% and causes cough. 
Ezhu Udarkattugal: 
           In Ezhuudalkattugal Saram was affected 100% and causes 
Envagai Thervugal: 
           According to study, Sparisam was affected in 100% of cases 
Naadi: 
 Vatham was observed in 16.7% 
 Vathapitham was observed in 43.33% 
 Vathakabam was observed in 23.33% 
 Pithavatham was observed in 16.7% 
 
Neerkuri: 
          Regarding Moothiram, neerkuri showed straw coloured urine in all cases 
Neikuri: 
          In the present study, 56.7% of cases was observed as Vatha neikuri, 6.6% of cases 
was observed as Pitha neikuri, 26.7% of cases was observed as Kaba neikuri. According 
to this neikuri, Vatham was dominantly affected.   
             
      The trail medicine chosen for the treatment of Puzhuvettu was “Silvisha 
Usidham” and “Puzhuvettu Thylam”.  
      The pharmacological studies already reported on the individual drugs also favor 
its effect in disease of Puzhuvettu (Alopecia areata) as given below. Elarisi have a potent 
immunomodulator, anti-inflammatory and anti fungal activity. Peyathi, Thippili and 
sesame oil have anti inflammatory and immunomodulator activity. Avuri have 
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antioxidant and effect on promoting hair growth. The Phytocemical analysis shows the 
presence of steroids and Psoralen a chemical constituent present in Ficus hispida.These 
are more effective in the management of Puzhuvettu. 
 
 According to SALT score: 
Grading was carried out based on subjective assessment as follows. 
 Grade I Slightly improvement barely noticeable (upto25%) 
 Grade II Moderate improvement noticeable (25-50%) 
 Grade III Obvious improvement    (50-75%) 
 Grade IV Marked improvement (>75%) 
 
                 Out of the 30 case, 56.7% of cases were obvious improvement, 40% of 
cases were moderate improvement and 3.33% were Slight improvement. These results 
were based on the clinical improvement by SALT score. The results of the study suggest 
that treatment with Silvisha Usidham and Puzhuvettu thylam has significant 
improvement in patients of Puzhuvettu. 
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7. SUMMARY 
 
 The aim of the study was Preclinical and clinical evaluation of Silvisha Usidham 
(Internal) and Puzhuvettu Thylam (External) for Puzhuvettu (Alopecia areata) in 
children.  
 Before initiating the clinical trial, approval was got from the Institutional Ethical 
committee of National Institute of Siddha (NIS/IEC/2016/11-20/14.10.2016) for 
conducting the clinical studies respectively by submitting the well defined protocol 
and proforma. It was registered prospectively in the Clinical Trail Registry of India 
(CTRI Reg No :CTRI/2018/01/011311)  
 The raw drugs were authenticated by the Assistant professor of medicinal botany 
and Investigator, Dept. of Gunapadam, NIS, and the trail drug was prepared by the 
investigator in the Gunapadam lab of National Institute of Siddha as per the 
standard operating procedure mentioned in the protocol.  
 The Phytochemical, physicochemical, heavy metal analysis, specific pathogen test, 
pesticide residue of the drug Silvisha Usidham were done in Noble Research 
Solution and the bio chemical qualitative analysis were done in the biochemistry 
lab of National Institute of Siddha. The biochemical analysis revealed the presence 
of Alkaloid, starch, silicate, Sulphate, carbonate, Iron and ammonium,.  
 The Physicochemical analysis of Silvisha Usidham constitutes alkaloid, steroids, 
Triterpenoids, coumarin and tanin. 
  Heavy metal analysis shows that the heavy metals like Lead, Cadmium, Arsenic 
and Mercury are within the permissible limits.  
  Analysis of microbial load reveals that the drug does not have any microbial    
 contamination. 
   The Silvisha Usidham does not show the evidence for the presence of any of the 
aflatoxins  and the Pesticide residue  values are within limit. 
  The Pharmacological studies were done. It revealed that the drug Silvisha 
Usidham possess Anti-inflammatory activities by In-vitro study.     
 The Children with Puzhuvettu were recruited based on inclusion and exclusion 
criteria and a detailed study was done. Separate proforma was maintained for each 
patient along with daily progress chart to monitor the prognosis. 
 Before initiating the trial informed consent was obtained from all the                                              
parents. 
116 
 
 2-3ml of Mantha ennai with luke warm water was administered at bedtime.Before 
starting the treatment to bring the vitiated vatham to normal.  
 The patients were treated for a period of 45 days. The trial medicine selected for the 
treatment was Silvisha Usidham (internal medicine) at the dose of 2-4ml twice a 
day  and Puzhuvettu Thylam (external) for 45 days as per Siddha literature 
Anuboga vaithiya navaneetham thirattu -  Part -10 ,Page no :108.  
 Clinical assessment was done during each visit in OPD patients (7 days once) and 
the data were noted in the prescribed proforma. (Form-IV) 
 During the study period there was no event of any adverse reactions were reported 
owing to the drug or disease.  
 Diet restriction was strictly followed during the period of drug administration as 
well as in re-dieting period as per noted in the dietary advice form .(Form-X)  
 The SALT score showed obvious improvement in 56.7%, moderate improvement 
in 40% and slight improvement in 3.33%. Statistical analysis done for SALT score 
and it shows that the trail drug Silvisha Usidham (Internal) and Puzhuvettu Thylam 
(External) is effective and it is consider significant  (p<0.001).   
 Thus the drug is found to be safe and effective in the management of Puzhuvettu. 
 The clinical efficacy of the drug was analyzed statistically by Salt score. The 
observation made during the clinical study showed that the trail drug Silvisha 
Usidham and Puzhuvettu Thylam was clinically effective.       
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8. CONCLUSION 
 
It is concluded by this study that Silvisha Usidham (Internal) and Puzhuvettu 
Thylam (External) is to be safe, efficacious and cost effective potent herbal drug in the 
treatment of Puzhuvettu. From the SALT score, finally it is concluded that 56.7% of case 
obvious improvement, 40% of cases moderate improvement and 3.33% of cases slight 
improvement. Statistical analysis done for SALT score shows that the trial drug Silvisha 
Usidham (Internal) and Puzhuvettu Thylam (External) is effective and p<0.0001 
considerable significant. There was no adverse reaction was reported during the trial 
period. The Clinical Trial conducted in selected patients was satisfactory and the results 
were encouraging.  However a study with large number of patients is required to find out 
the ideal dose response. 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
        DEPARTMENT OF KUZHANDHAI MARUTHUVAM PRECLINICAL AND 
CLINICAL EVALUATION OF SILVISHA USIDHAM (INTERNAL) AND 
PUZHUVETTU THYLAM (EXTERNAL) FOR PUZHUVETTU (ALOPECIA 
AREATA) IN CHILDREN.  
FORM I- SCREENING AND SELECTION FORM 
1.  S No:    2. OP/ IP No:                           3.Name:          
4. Age:    5.Gender:   6.Date of Enrollment:   
7. Date of completion: 8.Informant:   9.Reliability:   
INCLUSION CRETERIA:  
Age: between 6-12 years                         
Sex: Both male and female   
Patient who are satisfying minimum of 3 to 4 symptoms                                  Yes    No                                                                                                                        
Scattered long hairs within the bald area     
Non- scarring                                                        
The area of hair loss may tingle or be painful                        
Hair loss in patches                                                                      
EXCLUSION CRITERIA:  
Scarring alopecia                                                                                      
Alopecia universalis 
Alopecia totalis 
 Vitligo 
 Atopic dermatitis 
 Thyroid disease 
 Down syndrome 
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CHILDREN ADMITTED TO TRIAL: 1.Yes                    2.No 
                                                                   1. IP                       2.Op   
DATE:     SIGNATURE OF THE INVESTIGATOR:                         
STATION:    SIGNATURE OF THE GUIDE:                               
SIGNATURE OF THE HOD: 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI-47 
DEPARTMENT OF KUZHANDHAI MARUTHUVAM                                                         
FORM-II-   CONSENT FORM 
 
CERTIFICATE BY INVESTIGATOR 
 
 I certify that I have disclosed all the details about the study in the terms 
readily understood by the parent/guardian 
 
Signature  _________________ 
Name  _________________ 
Date   _________________ 
 
CONSENT BY PARENT 
 I have been informed to my satisfaction, by the attending physician, the purpose 
of the clinical trial, and the nature of drug treatment and follow-up including the 
laboratory investigations to be performed to monitor and safeguard my son/daughter 
body functions. 
 
 I am aware of my right to OPT my son/daughter out of the trail at any time during 
the course of the trail without having to give the reasons for doing so.  
 
 I, exercising my free power of choice, hereby give my consent to include my 
son/daughter as a subject in the Pre-clinical and clinical trial of SILVISHA USIDHA 
(Internal medicine) PUZHUVETTU THYLAM (External medicine) for 
“PUZHUVETTU” (Alopecia areata) in children.  
The photographs taken in the study will be displayed only in scientific conference for the 
advancement of medical knowledge. 
 
Date:     Signature  __________________ 
  
    Name             __________________  
Station:    
    Signature of witness  __________________ 
 
    Name   __________________ 
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NATIONAL INSTITUTE OF SIDDHA AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600047. 
                             DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
PRECLINICAL AND CLINICAL  EVALUATION OF SILVISHA USIDHAM 
(INTERNAL MEDICINE)AND PUZHUVETTU THYLAM (EXTERNAL 
MEDICINE) FOR PUZHUVETTU(ALOPECIA AREATA) IN CHILDREN. 
 
FORM- III   CASE RECORD FORM 
Demographic data 
OP/IP No. Visit Date : (__/__/____) 
Name :  
Age    :  
Gender                Male             Female Date Of Birth : (__/__/____) 
Father/ Mother /Guardian Name : 
 
 
Fathers Occupation : 
 
 
Fathers Monthly  Income : 
 
 
Religion : 
 
 
Socioeconomic Status :  
Patient Informant : 
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Postal Address: 
 
 
Contact No : 
 
 
1. Complaints and Duration 
 
2. Present illness 
 
3. History of Past Illness  
History /Symptoms/Signs  Yes  No  If, Yes Details 
Any Similar Complaints  
Bronchial Asthma 
Hospitalization 
Any other        _____________ 
Family History 
Any Hereditary/ Familial Disease                      Yes                      No 
If Yes, Details  -------- 
Immunization History  
Proper Immunization given  Yes                     No           
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Food habits: 
1. Veg  2. Non-Veg  
General assessment 
1. Pica 
2. Thumb sucking               
3. Nail biting 
4. Bowel movements 
5. Enuresis                           
General Examination 
1. Pallor    YES  NO 
2. Jaundice   YES  NO 
3. Cyanosis   YES  NO 
4. Clubbing   YES  NO 
5. Pedal oedema   YES  NO 
6. Lymph adenopathy  YES  NO 
Vital signs:- 
1. Pulse rate / mint 
2. Heart rate / mint 
3. Respiratory Rate / mint 
4. Temperature 
 
Anthropometry:- 
          Height- 
          Weight- 
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Examination of systems:          Normal        Affected 
Cardio – Vascular system:    
 
Gastro intestinal system:    
 
Central nervous system:        
 
Genito – urinary system: 
 
Endocrine system:    
 
Nilam:-  
   Kurinji Mullai                 Marutham           Neithal             Paalai 
 
KaalaIyalbu:-  
 Kaarkalam   Koothirkaalam      Munpanikaalam 
 Pinpanikaalam                       Illavenirkaalam      Muthuvenirkaalam 
Yaakai 
 Vatham  VathaPitham                VathaKabam 
 Pitham   Pithavatham   PithaKabam 
 Kabam   KabaVatham   KabaPitham 
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Gunam  
 Sathuvam   Rasatham   Thamasam 
Pori / Pulangal 
  Normal Affected  Normal Affected     Remarks 
Mei / unarvu 
Vaai / suvai  
Kan / parvai  
Mooku / natram 
Sevi / olli 
Kanmendhirium / Kanmavidayam 
       Normal     Affected       Normal            Affected 
 Remarks 
Kai / dhanam 
Kaal / ghamanam 
Vaai / vaku 
Eruvai / visarkam 
Karuvai / anantham 
UyirThathukkal 
Vali: 
   Normal Affected  Remarks 
Pranan  
Abanan 
Viyanan  
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Uthanan 
Samanan 
Nagan  
Koorman 
Kirukaran  
Devathathan   
Dhanajeyan    
Azhal  
   Normal Affected  Remarks 
Analam  
Ranjagam    
Saathagam   
Alosagam  
Prasagam 
 
Iyyam 
   Normal Affected  Remarks 
Avalambagam    
Kilethagam   
Pothagam  
Tharpagam   
Santhigam  
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Udalthathukkal 
   Normal Affected  Remarks 
Saaram 
Senneer  
Oon 
Kozhuppu 
Enbu 
Moolai 
Sukilam / Suronitham   
EnvagaiThervugal 
                   Normal  Affected  Remarks 
Naa 
 Niram 
 Thanmai 
 Suvai 
Niram   
Mozhi   
Vizhi  
 Niram 
 Thanmai 
 Parvai 
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Sparisam  
Malam 
 Niram   Normal Affected 
 Nurai   Normal Affected 
 Elagal   Yes                     No 
 Erugal   Yes                     No 
Moothiram 
Neerkuri:       Niram   Normal Affected 
  Edai   Normal Affected  
  Nurai             Normal  Affected 
  Manam            Normal  Affected  
  EnjalNeikuri  Normal Affected   
Neikuri: 
 Vatham  
  Pitham          
  Kabam         
  Others           
Naadi: 
ThaniNadi 
 Vadham  Pitham  Kabam 
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ThonthaNadi 
Vathapitham     Pitha vatham         Pitha kabam       Kabapitham 
ThodaNadi 
 Vatha kabam          Kaba vatham 
Mukkutra Nadi 
Diagnosis: 
DRUGS ISSUED: _____________ 
Date  : ___________________     
Station: ___________________  
Date: ___________________           
                                                                                                    
Signature of principle investigator 
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 NATIONAL INSTITUTE OF SIDDHA 
 AYOTHIDOSS  PANDITHAR  HOSPITAL, CHENNAI – 600 047. 
DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
PRECLINICAL AND CLINICAL  EVALUATION OF SILVISHA USIDHAM (INTERNAL 
MEDICINE) AND PUZHUVETTU THYLAM (EXTERNAL MEDICINE) FOR PUZHUVETTU 
(ALOPECIA AREATA) IN CHILDREN. 
 
1.  S No:    2. OP/ IP No:                           3.Name:          
4. Age:    5.Gender:   6.Date of Enrollment:   
7. Date of completion: 8.Informant:   9.Reliability:  
 
                                     CLINICAL ASSESSMENT FORM-IV 
SEVERITY OF ALOPECIA TOOL SCORE (SALT Score) 
 
DAYS SCALP SURFACE AREA MEASUREMENT 
SALT 
SCORE 
 
VERTEX 
AREA 
40% (0.4) 
RIGHT 
PROFILE 
AREA 18% 
(0.18) 
LEFT 
PROFILE 
AREA 
18% (0.18) 
POSTERIOR 
ASPECT OF 
SCALP 
AREA 24% 
(0.24) 
 
0
th
 day      
7
th
 day      
14
th
 day      
21
st
 day      
28
th
 day      
35
th
 day      
45
th
 day      
 
Date:                                                                              Signature of Principle Investigator 
Station:   
Signature of Lecturer:                                                   Signature of HOD:                                                                                                                                                                        
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                                       NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 DEPARTMENT OF KUZHANDHAI MARUTHUVAM  
PRECLINICAL AND CLINICAL EVALUATION OF SILVISHA USIDHAM         
(INTERNAL) AND PUZHUVETTU THYLAM  (EXTERNAL)  FOR 
PUZHUVETTU 
  (ALOPECIA AREATA)  IN CHILDREN. 
    FORM V -DRUG COMPLIANCE FORM 
S. NO: ---------   OPD/IPD NO: --------------- NAME: -----------------------        REG NO:  
Name of the drug: Silvisha Usidham 
Form of the drug: Oil 
Administration: Oral route 
Dose and Duration: 2-4ml twice daily for 45 days 
DAY     DATE    MORNING        NIGHT 
1    
2    
3    
4    
5    
6    
7    
8    
9    
10    
11    
12    
13    
14    
15    
16    
17    
18    
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Date:                                                                             Signature of  Principle Investigator 
Station:   
Signature of Lecturer:                                                  Signature of HOD:                                                                                                                                                                        
19    
20    
21    
22    
23    
24    
25    
26    
27    
28    
29    
30    
31    
32    
33    
34    
35    
36    
37    
38    
39    
40    
41    
42    
43    
44    
45    
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI-47 
FORM VI-A – PATIENT INFORMATION SHEET 
 
Name of principle investigator:   
I  Dr.R.D.Indumathi Studying as PG Scholar at National Institute of Siddha, 
Tambaram Sanatorium is doing a open clinical trial on “PUZHUVETTU” (Alopecia 
areata). Alopecia areata is a most common disease. In this regard, I am in a need to ask 
you few questions. I will maintain confidentiality of your comments and data obtained. 
There will be no risk of disclosing your identity and no physical, psychological or 
professional risk is involved by taking part in this study. Taking part in this study is 
voluntary. No compensation will be paid to you for taking part in this study. 
                  You have the liberty in choosing to take part in the study or not to take part. You 
can choose not to answer a specific question. You may be benefited if you take part in 
the study. Moreover, taking part in the study may be of benefit to the community, as it 
may help us to understand the problem of defaulters and potential solutions. 
        If you agree to be a participant in this study, you will be included in the study 
primarily by signing the consent form and then you will be given the internal medicine 
“SILVISHA USIDHAM” (2-4ml) and PUZHUVETTU THYLAM (External 
Medicine) for 45 days. 
           The information I am collecting in this study will remain between you and myself. 
I will ask you few questions through a questionnaire. The questionnaire will take 
approximately 20 minutes of your time. 
                         If you wish to find out more about this study before taking part, you can ask me all 
the questions you want or contact me (Dr.R.D.INDUMATHI) through 9092765785, PG 
scholar National Institute of Siddha, Chennai-47.  
          You can also contact the Member-secretary of Ethics committee, National Institute 
Siddha, Chennai 600047, Tel no: 91-44-22380789, for rights and participation in the 
study.  
Name:        Signature: 
Date: 
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தேசி஬ சித்ே ஫ருத்துல நிறுலனம் 
அத஬ோத்ேிேோச பண்டிேர் ஫ருத்துல஫னன சசன்னன-47 
குறந்னே ஫ருத்துலத்துனம 
 
பரிகரிப்புத் ேிமனனக் கண்டமியும் ஫ருத்துல ஆய்வு  
 
ஒப்புேல் படிலம் 
ஆய்லோர஭ோல் சோன்மரிக்கப்பட்டது.  
நோன் இந்ே ஫ருத்துல ஆய்னல குமித்ே அனனத்து லிப஭ங்கனரயும் தநோ஬ோரி஬ின் 
சபற்தமோருக்கு புரியும் லனக஬ில் எடுத்துன஭த்தேன் என உறுேி அரிக்கிதமன். 
 
தேேி:                                                னகச஬ோப்பம்: 
இடம்:                                                      சப஬ர்: 
 
தநோ஬ோரி஬ின் சபற்தமோர் ஒப்புேல் படிலம் 
என்னிடம் இந்ே ஫ருத்துல ஆய்லின் கோ஭ணத்னேயும்,஫ருந்ேின் ேன்ன஫ ஫ற்றும் 
஫ருத்துல லறிமுனமப் பற்மியும், இந்ே ஫ருத்துலத்னே சேோடர்ந்து எனது குறந்னே஬ின் 
உடல் இ஬க்கத்னேக் கண்கோணிக்கவும்,அேனனத் போதுகோக்க ப஬ன்படும் ஫ருத்துல 
ஆய்வுக்கூடப் பரிதசோேனனகள் பற்மியும் ேிருப்ேி அரிக்கும் லனக஬ில் ஆய்வு 
஫ருத்துல஭ோல் லிரக்கிக் கூமப்பட்டது. 
நோன் இந்ே ஫ருத்துல ஆய்லின் தபோது கோ஭ணம் எதுவும் கூமோ஫ல் எப்தபோது 
தலண்டு஫ோனோலும் என் குறந்னேன஬ லிடுலித்துக் சகோள்ளும் உரின஫ன஬ 
சேரிந்ேிருக்கிதமன். 
நோன் என்னுனட஬ சுேந்ேி஭஫ோக தேர்வு சசய்யும் உரின஫ன஬க் சகோண்டு புழுவயட்டு 
தநோய்க்கோன ெில்யிர உெிதம் (உள்நபேந்து) நற்றும் புழுவயட்டு லத஬ம்(வய஭ிநபேந்து) 
பரிகரிப்புத் ேிமனன கண்டமியும் ஫ருத்துல ஆய்வுக்கு எனது குறந்னேன஬ உட்படுத்ே 
ஒப்புேல் அரிக்கிதமன். 
 
தேேி:                                                              சபற்தமோர் சப஬ர் : 
இடம்:                                                             னகச஬ோப்பம்:                                                                  
                         
                                                                                                         சோட்சிக்கோ஭ர் சப஬ர்:                                     
          னகச஬ோப்பம்: 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
PRECLINICAL AND CLINICAL EVALUATION OF SILVISHA USIDHAM  
(INTERNAL) AND PUZHUVETTU THYLAM (EXTERNAL) FOR 
PUZHUVETTU (ALOPECIA AREATA) IN CHILDREN. 
Principle Investigator: Dr.R.D.INDUMATHI 
1.  S.I No:        2. OP/ IP No:                      3.Name:                                                   
4. Age:       5.Gender:   6.Date of Enrollment: 
7. Date of completion:     8.Informant:  9.Reliablity:  
FORM-VI WITHDRAWAL FORM                                        
10. DATE OF TRIAL COMMENCEMENT: ………………... 
11. DATE OF WITHDRAWAL FROM TRIAL: …………….. 
12.REASONS FOR WITHDRAWAL: 
Long absence at reporting:                Yes/ No 
Irregular treatment:                            Yes/ No 
Shift of locality:                                      Yes/No 
Increase in severity of symptoms:      Yes/No 
Development of severe adverse drug reactions:    Yes/No 
Development of adverse event:                                               Yes/No 
 (If YES, give the details of adverse reaction in Adverse Reaction Form / 
Pharmaco Vigilance Form) 
 
Date:          
Station: 
 
Signature of the Investigator: 
Signature of the Guide:                                                         Signature of the HOD 
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1. Patient / consumer identification (please complete or tick boxes below as 
appropriate) 
        NATIONAL PHARMACOVIGILANCE PROGRAMME FOR  SIDDHA DRUGS 
 
 
Please note:  i.  All consumers / patients and reporters information will remain 
confidential. 
                       ii. It is requested to report all suspected reactions to the concerned, even if  
it does not have complete data, as soon as possible. 
Peripheral Center code:     State: 
Name Father name Patient / Record 
No. Ethnicity Occupation 
Address  
Village / Town 
Post / Via 
District / State    
Date of Birth / 
Age: 
Sex:     M / F  
Weight : 
Degam: 
 
2. Description of the suspected Adverse Reactions (please complete boxes below) 
Date and time  of 
initial observation 
 Season: 
Description of 
reaction   
 Geographical area: 
 
Reporting Form for Suspected Adverse Reactions to Siddha 
Drugs 
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3. List of all medicines / Formulations including drugs of other systems used by the 
patient during the reporting period: 
Medicine Daily 
dose 
Route of 
administration 
& Vehicle - 
Adjuvant 
Date  Diagnosis for 
which medicine 
taken  
Starting Stopped 
Siddha 
     
Any other 
system of 
medicines 
     
 
4. Brief details of the Siddha Medicine which seems to be toxic : 
Details Drug – 1 Drug – 2 Drug - 3 
a) Name of the medicine    
b) Manufacturing unit 
and batch No. and date 
   
c) Expiry date    
d) Purchased and 
obtained from 
   
e) Composition of the 
formulation / Part of the 
drug used 
   
 
b) Dietary Restrictions if any 
c) Whether the drug is consumed under institutionally qualified medical supervision or 
used as self medication.  
d) Any other relevant information. 
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5. Treatment provided for adverse reaction: 
6. The result of the adverse reaction / side effect / untoward effects (please complete 
the boxes below) 
Recovered:      Not 
recovered: 
 Unknown: Fatal: If Fatal 
Date of death: 
Severe:   Yes   /   
No. 
Reaction abated after drug stopped or dose reduced: 
Reaction reappeared after re introduction: 
Was the patient 
admitted to 
hospital? If yes, 
give name and 
address of hospital 
 
 
7. Any laboratory investigations done to evaluate other possibilities?  If Yes specify:  
8. Whether the patient is suffering with any chronic disorders? 
Hepatic    Renal    Cardiac    Diabetes    Malnutrition    
 
Any Others  
 
9. H/O previous allergies / Drug reactions:  
 
 
10. Other illness (please describe): 
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11. Identification of the reporter: 
Type (please tick):  Nurse / Doctor / Pharmacist / Health worker / Patient / 
Attendant / Manufacturer /                                                                      
                                Distributor / Supplier / Any others (please specify) 
Name: 
 
Address: 
 
Telephone / E – mail if any : 
 
 
 
Signature of the reporter:          Date: 
 
Please send the completed form to:  
                The Director 
                National Institute of Siddha, 
                                                           (Pharmacovigilance Regional Centre For Siddha      
                                                             Medicine), 
                                                           Tambaram Sanatorium, Chennai-600 047. 
                                                            (O) 044-22381314       Fax : 044 – 22381314 
        Website : www.nischennai.org  
        Email: nischennaisiddha@yahoo.co.in   
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * ** * * * * 
Name & address of the RRC-
ASU / PPC-ASU 
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This filled-in ADR report may be sent within one month of observation /occurrence 
of ADR   
 
 
 
 
 
 
 
 
Date:                                                                              
Station:  
Signature of the Investigator: 
Signature of the Lecturer:                                                           Signature of the HOD 
  
Who Can Report? 
 Any Health care professionals like Siddha Doctors /  
Nurses / Siddha Pharmacists / Patients etc.  
What to Report?  
 All reactions,  Drug interactions,  
Confidentiality  
 The patient’s identity will be held in strict confidence 
and protected to the fullest extent.  
 Submission of report will be taken up for remedial 
measures only not for legal claim  
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
PRECLINICAL AND CLINICAL EVALUATION OF SILVISHA USIDHAM 
(INTERNAL) AND PUZHUVETTU THYLAM (EXTERNAL) FOR 
PUZHUVETTU (ALOPECIA AREATA) IN CHILDREN. 
 
FORM IX  -  DIETARY ADVICE FORM 
 
 THINGS TO TAKE  THINGS TO AVOID 
Non animal source of protein (Grain, Nuts and 
Seeds)  
Animal fat (meat) 
Foods that are high in calcium (Soya products, 
nuts, nut milks)  
Acidic foods 
Healthy fats (Olive oil, Walnuts, Canola oil) Milk and Dry Products 
Fresh fruits and Vegetables  Refined food like Bakery items  
Vitamin B rich foods (Nuts, Carrots) Oily and greasy food 
 
஫ருத்துல அமிவுன஭ ஫ற்றும் உணவு அமிவுன஭-கனடப்பிடிக்க: 
 உணலில்஫ிரகு,இஞ்சி,சுக்கு,஫ஞ்சள்அேிக஫ோகதசர்க்கவும். 
 பசும்போயில்பனங்கற்கண்டு,ஏயக்கோய்இட்டுகோய்ச்சிே஭வும். 
 பப்போரி,சகோய்஬ோ,சப்தபோட்டோ,஫ோதுனரதபோன்மபறலனககனரகோனயஅல்ய
து஫ேி஬தலனர஬ில்ே஭வும். 
 கோய்கமிகீன஭லனககனரேினமும்உணலில்தசர்க்கவும் 
 ஫ிே஫ோனசுடுநீரில்குரிப்போட்டவும் 
ேலிர்க்க: 
 தூசி, ஒட்டனட,஫ோசுபடிந்ேசூறனயேலிர்க்கவும் 
 குரிர்ந்ேகோற்று,குரிர்சோேனசபட்டிஉணவுகனரேலிர்க்கவும். 
 சச஬ற்னகஇனிப்புேிண்பண்டங்கரோன஫ிட்டோய்,கிரீம்தசர்ந்ேதகக்,பிஸ்கட்டுக
னரநீக்கவும். 
 உணவுஉண்டபின்குரிப்போட்டுலனேேலிர்க்கவும். 
 ஫ோ஫ிசஉணலில்பி஭ோய்யர்தகோறின஬ேலிர்க்கவும். 
145 
 
NATIONAL INSTITUTE OF SIDDHA, 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI-600047. 
DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
PRECLINICAL AND CLINICAL EVALUATION OF SILVISHA USIDHAM 
(INTERNAL) AND PUZHUVETTU THYLAM (EXTERNAL) FOR PUZHUVETTU 
(ALOPECIA AREATA) IN CHILDREN. 
 
FORM-X ASSENT FORM  
I,      understand that my parents (mom and 
dad)/guardian have/has given permission (said it‟s okay) for me to take part in a project 
about done by  .      
I am taking part because I want to.  I have been told that I can stop at any time I 
want to and nothing will happen to me if I want to stop. 
       
      
Signature 
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Post Graduate Thesis Yes
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Type of Study Drug
Siddha
Study Design Other
Public Title of Study PUZHUVETTU (Alopecia areata) in Children - Silvisha usidham (Internal) and Puzhuvettu thylam
(External)
Scientific Title of
Study
Preclinical and Clinical evaluation of Silvisha Usidham (Internal) and Puzhuvettu Thylam (External)
for Puzhuvettu (Alopecia areata) in Children.
Secondary IDs if Any Secondary ID Identifier
NIL NIL
Details of Principal
Investigator or overall
Trial Coordinator
(multi-center study)
Details of Principal Investigator
Name Dr R D Indumathi
Designation PG Scholar
Affiliation National Institute of Siddha
Address National Institute of Siddha Tambaram Sanatorium Chennai 47
National Institute of Siddha Tambaram Sanatorium Chennai 47
Kancheepuram
TAMIL NADU
6000047
India
Phone 9092765785
Fax
Email indubsms@gmail.com
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Designation Head of the Department
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Phone 9092765785
Fax
Email indubsms@gmail.com
Source of Monetary or
Material Support
Source of Monetary or Material Support
> Kuzhandai Maruthuvam National Institute of Siddha Ayothidoss pandithar Hospital Tambaram
Sanatorium Chennai 47
Primary Sponsor Primary Sponsor Details
Name Ayodhidoss Pandithar Hospital
Address National Institute of Siddha Tambaram Sanatorium Chennai 47
Type of Sponsor Research institution and hospital
Details of Secondary
Sponsor
Name Address
NIL NIL
Countries of
Recruitment
List of Countries
India
Sites of Study Name of Principal
Investigator 
Name of Site Site Address Phone/Fax/Email
R D Indumathi National Institute of
Siddha
Kuzhandai
Maruthuvam, Room no
4 National Institute of
Siddha Tambaram
Sanatorium Chennai
Kancheepuram
TAMIL NADU
9092765785
indubsms@gmail.com
Details of Ethics
Committee
Name of Committee Approval Status Date of Approval Is Independent Ethics
Committee?
Institutional Ethical
Committee
Approved 14/10/2016 No
Regulatory Clearance
Status from DCGI
Status Date
Not Applicable No Date Specified
Health Condition /
Problems Studied
Health Type Condition
Patients Puzhuvettu (Alopecia areata)
Intervention /
Comparator Agent
Type Name Details
Intervention Silvisha Usidham Puzhuvettu
Thylam
2-4ml of Silvisha Usidham will
be orally twice a day for a
period of 45days Puzhuvettu
Thylam will be apply externally
for 45days
Comparator Agent Silvisha Usidham Puzhuvettu
Thylam
2-4ml of Silvisha Usidham will
be orally twice a day for a
period of 45days Puzhuvettu
Thylam will be apply externally
for 45days
Inclusion Criteria Inclusion Criteria
Age From 6.00 Year(s)
Age To 12.00 Year(s)
Gender Both
Details 1 Patchy hair loss in the scalp
2 Non Scarring
3 Scattered long hair within bald area
4 Patient who is willing to be admitted in the hospital or willing to
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attend OPD when required
5 Willing to sign the informed and consent form
Exclusion Criteria Exclusion Criteria
Details 1 Scarring alopecia
2 Alopecia totalis
3 Alopecia universalis
4 Thyroid disease
5 Atopic dermatitis
6 Vitiligo
7 Pernicious anaemia
8 Down syndrome
Method of Generating
Random Sequence
Not Applicable
Method of
Concealment
Case Record Numbers
Blinding/Masking Open Label
Primary Outcome Outcome Timepoints
It is mainly assessed by SALT Score 45 days
Secondary Outcome Outcome Timepoints
Comparing the improvement of clinical
symptoms before and after treatment
45days
Target Sample Size Total Sample Size=30
Sample Size from India=30
Phase of Trial Phase 2
Date of First
Enrollment (India)
30/12/2017
Date of First
Enrollment (Global)
No Date Specified
Estimated Duration of
Trial
Years=2
Months=0
Days=0
Recruitment Status of
Trial (Global)
Not Applicable
Recruitment Status of
Trial (India)
Open to Recruitment
Publication Details Not yet
Brief Summary It is a single,non randamized open - label trial to determine the efficacy
and safety of SILVISHA  USIDHAM  and  PUZHUVETTU THYLAM
in patients with PUZHUVETTU (ALOPECIA AREATA).In this trail
30 alopecia areata patients will be recruited  and the trail drug
(Internal) will be administrated 2-4ml twice a day for a period of 45
days and External drug will be apply for 45days during the study
period all the study related data will be recorded and documented in a
separate trail master file for each patients. During the trail period if
any adverse effect will be noticed and referred to pharmacovigilance
dept.in NIS and further management will also be given in NIS OPD and
IPD. The entire trail will be monitored by the research monitoring
committee of NIS . During this trail all the safety and efficacy
parameters will be recorded in the CFR.After the completion of the
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trail all the study related data will be analysed statistically the outcome
of this trail will be published in Indian Journal of Medical Research.
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